NZ710003B2 - Positive allosteric modulators of nicotinic acetylcholine receptor - Google Patents
Positive allosteric modulators of nicotinic acetylcholine receptor Download PDFInfo
- Publication number
- NZ710003B2 NZ710003B2 NZ710003A NZ71000312A NZ710003B2 NZ 710003 B2 NZ710003 B2 NZ 710003B2 NZ 710003 A NZ710003 A NZ 710003A NZ 71000312 A NZ71000312 A NZ 71000312A NZ 710003 B2 NZ710003 B2 NZ 710003B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- phenyl
- amide
- ethyl
- acid
- Prior art date
Links
- 230000000051 modifying Effects 0.000 title abstract description 18
- 230000003281 allosteric Effects 0.000 title abstract description 7
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 title description 38
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 title description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 315
- 201000010099 disease Diseases 0.000 claims abstract description 58
- -1 6-ethoxy-pyridinyl Chemical group 0.000 claims description 83
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 35
- 230000003042 antagnostic Effects 0.000 claims description 34
- 239000005557 antagonist Substances 0.000 claims description 33
- 239000011780 sodium chloride Substances 0.000 claims description 32
- 206010057668 Cognitive disease Diseases 0.000 claims description 30
- 201000000980 schizophrenia Diseases 0.000 claims description 27
- 125000004429 atoms Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 206010061536 Parkinson's disease Diseases 0.000 claims description 21
- 206010012289 Dementia Diseases 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- IWWCCNVRNHTGLV-UHFFFAOYSA-N 1-phenylcyclopropane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CC1 IWWCCNVRNHTGLV-UHFFFAOYSA-N 0.000 claims description 17
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 16
- 208000006264 Korsakoff Syndrome Diseases 0.000 claims description 16
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 16
- 239000003112 inhibitor Substances 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims description 16
- 101700044444 TKT Proteins 0.000 claims description 15
- 102100002615 TKT Human genes 0.000 claims description 15
- 230000001149 cognitive Effects 0.000 claims description 13
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 12
- 230000036407 pain Effects 0.000 claims description 12
- 210000004558 Lewy Bodies Anatomy 0.000 claims description 11
- 201000011240 frontotemporal dementia Diseases 0.000 claims description 10
- 230000011664 signaling Effects 0.000 claims description 10
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 9
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 9
- 201000010374 Down syndrome Diseases 0.000 claims description 9
- 206010015037 Epilepsy Diseases 0.000 claims description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 9
- 201000001971 Huntington's disease Diseases 0.000 claims description 9
- 206010044688 Trisomy 21 Diseases 0.000 claims description 9
- 229960003692 aminobutyric acid Drugs 0.000 claims description 9
- 230000002708 enhancing Effects 0.000 claims description 9
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 8
- 201000011585 Pick's disease Diseases 0.000 claims description 8
- 230000033115 angiogenesis Effects 0.000 claims description 8
- 229960003638 dopamine Drugs 0.000 claims description 8
- 230000002829 reduced Effects 0.000 claims description 8
- 238000004260 weight control Methods 0.000 claims description 8
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 7
- 102100006205 HTR2A Human genes 0.000 claims description 7
- 101710045394 HTR2A Proteins 0.000 claims description 7
- 206010036309 Post-traumatic amnestic disease Diseases 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 7
- 125000002950 monocyclic group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 6
- 206010061920 Psychotic disease Diseases 0.000 claims description 6
- 239000003194 amino acid receptor blocking agent Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003825 glutamate receptor antagonist Substances 0.000 claims description 6
- 200000000018 inflammatory disease Diseases 0.000 claims description 6
- 206010027175 Memory impairment Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- WSWPQUMAYACYMY-UHFFFAOYSA-N lithium;sodium Chemical compound [Li+].[Na+] WSWPQUMAYACYMY-UHFFFAOYSA-N 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 208000001183 Brain Injury Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical group CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 93
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 15
- 229960004373 Acetylcholine Drugs 0.000 abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 125
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 106
- 239000002253 acid Substances 0.000 description 99
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 64
- 235000019439 ethyl acetate Nutrition 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 54
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 53
- 239000000243 solution Substances 0.000 description 50
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- 239000007787 solid Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
- 239000012267 brine Substances 0.000 description 28
- 210000004027 cells Anatomy 0.000 description 24
- 229910052805 deuterium Inorganic materials 0.000 description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- 230000035492 administration Effects 0.000 description 19
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 19
- 235000013350 formula milk Nutrition 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 235000019341 magnesium sulphate Nutrition 0.000 description 18
- 229910052796 boron Inorganic materials 0.000 description 16
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Inorganic materials [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 16
- 239000011737 fluorine Substances 0.000 description 15
- 229910052731 fluorine Inorganic materials 0.000 description 15
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drugs Drugs 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000007792 addition Methods 0.000 description 13
- 201000007185 autism spectrum disease Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000003818 flash chromatography Methods 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 206010003736 Attention deficit/hyperactivity disease Diseases 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 201000006287 attention deficit hyperactivity disease Diseases 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 210000000287 oocyte Anatomy 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000004808 supercritical fluid chromatography Methods 0.000 description 11
- 241000229754 Iva xanthiifolia Species 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 9
- 230000003287 optical Effects 0.000 description 9
- 206010070976 Craniocerebral injury Diseases 0.000 description 8
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 210000003169 Central Nervous System Anatomy 0.000 description 7
- 206010039966 Senile dementia Diseases 0.000 description 7
- 238000004166 bioassay Methods 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 230000015654 memory Effects 0.000 description 7
- 229940073584 methylene chloride Drugs 0.000 description 7
- 229960001866 silicon dioxide Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- JNWBBCNCSMBKNE-UHFFFAOYSA-N HATU Chemical compound F[P-](F)(F)(F)(F)F.C1=CN=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 JNWBBCNCSMBKNE-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000003195 sodium channel blocking agent Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940086542 triethylamine Drugs 0.000 description 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 5
- 229960002715 Nicotine Drugs 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000012230 colorless oil Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 230000000155 isotopic Effects 0.000 description 5
- 229930015196 nicotine Natural products 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- PEAOEIWYQVXZMB-UHFFFAOYSA-N 5-bromo-2-chloropyridine Chemical compound ClC1=CC=C(Br)C=N1 PEAOEIWYQVXZMB-UHFFFAOYSA-N 0.000 description 4
- HGGHHALBPHBHNP-UHFFFAOYSA-N 6-bromo-[1,3]dioxolo[4,5-b]pyridine Chemical compound BrC1=CN=C2OCOC2=C1 HGGHHALBPHBHNP-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- VQJXDRJDCCSIQA-LURJTMIESA-N FC(COC=1C=CC(=NC=1)[C@H](C)[NH-])(F)F Chemical compound FC(COC=1C=CC(=NC=1)[C@H](C)[NH-])(F)F VQJXDRJDCCSIQA-LURJTMIESA-N 0.000 description 4
- 239000001828 Gelatine Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M Sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
- 239000001963 growth media Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YOMWYEITAAOYEC-AWGJQOPUSA-N (2R)-butane-2-sulfinamide Chemical compound CC[C@@H](C)S(N)=O YOMWYEITAAOYEC-AWGJQOPUSA-N 0.000 description 3
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 3
- KXBXUHWCODHRHK-UHFFFAOYSA-N 5-bromo-3-hydroxy-1H-pyridin-2-one Chemical compound OC1=CC(Br)=CNC1=O KXBXUHWCODHRHK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010003805 Autism Diseases 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 229960001375 Lactose Drugs 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- 229940057948 Magnesium stearate Drugs 0.000 description 3
- CEIIEALEIHQDBX-UHFFFAOYSA-N PNU-120,596 Chemical compound C1=C(Cl)C(OC)=CC(OC)=C1NC(=O)NC1=NOC(C)=C1 CEIIEALEIHQDBX-UHFFFAOYSA-N 0.000 description 3
- 235000019483 Peanut oil Nutrition 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 201000002055 autistic disease Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229960001078 lithium Drugs 0.000 description 3
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminum hydride Chemical compound [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 230000000324 neuroprotective Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- AHDDRJBFJBDEPW-BDAKNGLRSA-N (1S,2S)-2-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)[C@H]1C[C@@H]1C1=CC=CC=C1 AHDDRJBFJBDEPW-BDAKNGLRSA-N 0.000 description 2
- RUCZFWMEACWFER-UHFFFAOYSA-N (5-bromopyridin-2-yl)methanol Chemical compound OCC1=CC=C(Br)C=N1 RUCZFWMEACWFER-UHFFFAOYSA-N 0.000 description 2
- YVPJCJLMRRTDMQ-ONEGZZNKSA-N (E)-2-diazonio-1-ethoxyethenolate Chemical compound CCO\C([O-])=C\[N+]#N YVPJCJLMRRTDMQ-ONEGZZNKSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- ZJSKEGAHBAHFON-UHFFFAOYSA-N 1-ethenyl-3-fluorobenzene Chemical compound FC1=CC=CC(C=C)=C1 ZJSKEGAHBAHFON-UHFFFAOYSA-N 0.000 description 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 2
- AHDDRJBFJBDEPW-UHFFFAOYSA-N 2-phenylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1CC1C1=CC=CC=C1 AHDDRJBFJBDEPW-UHFFFAOYSA-N 0.000 description 2
- NNEDVBTXDIIWNX-UHFFFAOYSA-N 3-(3-bromopropoxy)pyridine Chemical compound BrCCCOC1=CC=CN=C1 NNEDVBTXDIIWNX-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-Hydroxyindole Chemical compound OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 description 2
- FSZRSTNRZUIEMA-UHFFFAOYSA-N 5-bromo-2-propan-2-yloxypyridine Chemical compound CC(C)OC1=CC=C(Br)C=N1 FSZRSTNRZUIEMA-UHFFFAOYSA-N 0.000 description 2
- CNZWBNAVIYOMMR-UHFFFAOYSA-N 63324-95-8 Chemical compound O=C1C2=CC(O)=CC(O)=C2C(=O)C(C(O)=C23)=C1C=C3OC1C2CC(O)O1 CNZWBNAVIYOMMR-UHFFFAOYSA-N 0.000 description 2
- 230000035533 AUC Effects 0.000 description 2
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 229940022698 Acetylcholinesterase Drugs 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N Benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 101710022327 Bom23 Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 206010017374 Friedreich's ataxia Diseases 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 101700056845 IM23 Proteins 0.000 description 2
- 101700012363 IM25 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- OYVXVLSZQHSNDK-UHFFFAOYSA-N N-methoxy-N-methylacetamide Chemical compound CON(C)C(C)=O OYVXVLSZQHSNDK-UHFFFAOYSA-N 0.000 description 2
- 101710002980 Os01g0895100 Proteins 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 2
- 229940067631 Phospholipids Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N Probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940083542 Sodium Drugs 0.000 description 2
- 229940054269 Sodium Pyruvate Drugs 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 108060008443 TPPP Proteins 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000001270 agonistic Effects 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-N calcium;sulfuric acid Chemical compound [Ca+2].OS(O)(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N cdcl3 Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000001713 cholinergic Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000002301 combined Effects 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 2
- AULAXUOXHOEPKW-WDEREUQCSA-N ethyl (1R,2R)-2-(3-fluorophenyl)cyclopropane-1-carboxylate Chemical compound CCOC(=O)[C@@H]1C[C@H]1C1=CC=CC(F)=C1 AULAXUOXHOEPKW-WDEREUQCSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000004962 mammalian cells Anatomy 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000000546 pharmaceutic aid Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001690 polydopamine Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001953 sensory Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 229960001322 trypsin Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 201000004810 vascular dementia Diseases 0.000 description 2
- 230000001755 vocal Effects 0.000 description 2
- HOHNIANSOKBRLC-MRVPVSSYSA-N (1R)-2-amino-1-(6-methylpyridin-2-yl)ethanol Chemical compound CC1=CC=CC([C@H](O)CN)=N1 HOHNIANSOKBRLC-MRVPVSSYSA-N 0.000 description 1
- QBMFTTZBSGXNML-FJXQXJEOSA-N (1S)-1-(5-methylpyridin-2-yl)ethanamine;hydrochloride Chemical compound Cl.C[C@H](N)C1=CC=C(C)C=N1 QBMFTTZBSGXNML-FJXQXJEOSA-N 0.000 description 1
- NQMOEOWCGIQVCO-LURJTMIESA-N (1S)-1-(6-methoxypyridin-2-yl)ethanamine Chemical compound COC1=CC=CC([C@H](C)N)=N1 NQMOEOWCGIQVCO-LURJTMIESA-N 0.000 description 1
- WYWLBJSLKUQLHT-ZETCQYMHSA-N (1S)-1-(6-methylpyridin-2-yl)ethanamine Chemical compound C[C@H](N)C1=CC=CC(C)=N1 WYWLBJSLKUQLHT-ZETCQYMHSA-N 0.000 description 1
- JNODDICFTDYODH-BYPYZUCNSA-N (2S)-oxolan-2-ol Chemical compound O[C@@H]1CCCO1 JNODDICFTDYODH-BYPYZUCNSA-N 0.000 description 1
- XDPCNPCKDGQBAN-SCSAIBSYSA-N (3R)-oxolan-3-ol Chemical compound O[C@@H]1CCOC1 XDPCNPCKDGQBAN-SCSAIBSYSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-Dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- BQOZPPQLJJSAAG-UHFFFAOYSA-N 1,2-dichloroethane;methanediimine Chemical compound N=C=N.ClCCCl BQOZPPQLJJSAAG-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ICILFNKGOOEYFQ-UHFFFAOYSA-N 1-(2-ethoxypyridin-3-yl)ethanone Chemical compound CCOC1=NC=CC=C1C(C)=O ICILFNKGOOEYFQ-UHFFFAOYSA-N 0.000 description 1
- KFBYRBFYHOJYTG-UHFFFAOYSA-N 1-(6-chloropyridin-2-yl)ethanone Chemical compound CC(=O)C1=CC=CC(Cl)=N1 KFBYRBFYHOJYTG-UHFFFAOYSA-N 0.000 description 1
- KRIWTLNXGHIQDF-UHFFFAOYSA-N 1-(6-ethylpyridin-3-yl)ethanone Chemical compound CCC1=CC=C(C(C)=O)C=N1 KRIWTLNXGHIQDF-UHFFFAOYSA-N 0.000 description 1
- JJDVJVUNHSDOIO-UHFFFAOYSA-N 1-[6-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethanone Chemical compound CC(=O)C1=CC=CC(OCC(F)(F)F)=N1 JJDVJVUNHSDOIO-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- JWVTWJNGILGLAT-UHFFFAOYSA-N 1-ethenyl-4-fluorobenzene Chemical compound FC1=CC=C(C=C)C=C1 JWVTWJNGILGLAT-UHFFFAOYSA-N 0.000 description 1
- CQMJEZQEVXQEJB-UHFFFAOYSA-N 1-hydroxy-1,3-dioxobenziodoxole Chemical compound C1=CC=C2I(O)(=O)OC(=O)C2=C1 CQMJEZQEVXQEJB-UHFFFAOYSA-N 0.000 description 1
- AZJIXRYFAZOEMC-UHFFFAOYSA-N 1-hydroxy-3-oxobenziodoxole Chemical compound C1=CC=C2I(O)OC(=O)C2=C1 AZJIXRYFAZOEMC-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- YNISDSFVUCOJFJ-UHFFFAOYSA-N 2-(2-bromoethoxy)pyridine Chemical compound BrCCOC1=CC=CC=N1 YNISDSFVUCOJFJ-UHFFFAOYSA-N 0.000 description 1
- HOVQIIGVBKXWRZ-UHFFFAOYSA-N 2-amino-4-methoxy-3-pentoxybenzaldehyde Chemical compound CCCCCOC1=C(N)C(C=O)=CC=C1OC HOVQIIGVBKXWRZ-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- LISKAOIANGDBTB-UHFFFAOYSA-N 2-ethoxypyridine Chemical compound CCOC1=CC=CC=N1 LISKAOIANGDBTB-UHFFFAOYSA-N 0.000 description 1
- AEXIQPQOFKQACC-UHFFFAOYSA-N 2-ethoxypyrimidine Chemical compound CCOC1=NC=CC=N1 AEXIQPQOFKQACC-UHFFFAOYSA-N 0.000 description 1
- IFZZDINNCWFGEO-UHFFFAOYSA-N 2-propan-2-yloxypyridine Chemical compound CC(C)OC1=CC=CC=N1 IFZZDINNCWFGEO-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 description 1
- RPYWXZCFYPVCNQ-RVDMUPIBSA-N 3-[(5E)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2H-pyridin-6-yl]pyridine Chemical compound COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 RPYWXZCFYPVCNQ-RVDMUPIBSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- URMFHFVYCDGDEC-UHFFFAOYSA-N 3-ethoxypyridine Chemical compound CCOC1=CC=CN=C1 URMFHFVYCDGDEC-UHFFFAOYSA-N 0.000 description 1
- LUKNJAQKVPBDSC-SFHVURJKSA-N 5-[6-[[(3R)-1-azabicyclo[2.2.2]octan-3-yl]oxy]pyridazin-3-yl]-1H-indole Chemical compound C1=C2NC=CC2=CC(C2=CC=C(N=N2)O[C@@H]2C3CCN(C2)CC3)=C1 LUKNJAQKVPBDSC-SFHVURJKSA-N 0.000 description 1
- JSYQQBQGDIUUFS-UHFFFAOYSA-N 5-bromo-2-(2,2,2-trifluoroethoxy)pyridine Chemical compound FC(F)(F)COC1=CC=C(Br)C=N1 JSYQQBQGDIUUFS-UHFFFAOYSA-N 0.000 description 1
- WQXZKMUZWPUZGL-UHFFFAOYSA-N 5-bromo-2-ethoxypyridine Chemical compound CCOC1=CC=C(Br)C=N1 WQXZKMUZWPUZGL-UHFFFAOYSA-N 0.000 description 1
- ZQVLPMNLLKGGIU-UHFFFAOYSA-N 5-bromopyridine-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)N=C1 ZQVLPMNLLKGGIU-UHFFFAOYSA-N 0.000 description 1
- SIYQPUXDOVLHGU-ZETCQYMHSA-N 6-[(1R)-1-amino-2-hydroxyethyl]pyridine-3-carbonitrile Chemical compound OC[C@H](N)C1=CC=C(C#N)C=N1 SIYQPUXDOVLHGU-ZETCQYMHSA-N 0.000 description 1
- PMNCDNRJLYPTDB-UHFFFAOYSA-N 7-bromo-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine Chemical compound O1CCOC2=CC(Br)=CN=C21 PMNCDNRJLYPTDB-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7H-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229940025084 Amphetamine Drugs 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003484 Asperger's disease Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 229940116592 CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 101710004532 CG33470 Proteins 0.000 description 1
- 229960004424 Carbon Dioxide Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008522 Childhood disintegrative disease Diseases 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 102000020504 Collagenase family Human genes 0.000 description 1
- 108060005980 Collagenase family Proteins 0.000 description 1
- 241000013987 Colletes Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010067889 Dementia with Lewy body Diseases 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N Dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N Diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 1
- 102000027732 GABAA receptors Human genes 0.000 description 1
- 108091008003 GABAA receptors Proteins 0.000 description 1
- 229960003980 Galantamine Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 210000004517 Glycocalyx Anatomy 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- 210000001320 Hippocampus Anatomy 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 210000001153 Interneurons Anatomy 0.000 description 1
- 229940119837 Isopropyl Alcohol Drugs 0.000 description 1
- 229960002418 Ivermectin Drugs 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 102100014726 MECP2 Human genes 0.000 description 1
- 101700029603 MECP2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- 206010028640 Myopathy Diseases 0.000 description 1
- UYEKHNCKLMEBRX-UHFFFAOYSA-N N,6-diethylpyridin-2-amine Chemical compound CCNC1=CC=CC(CC)=N1 UYEKHNCKLMEBRX-UHFFFAOYSA-N 0.000 description 1
- HWWVAHCWJLGKLW-UHFFFAOYSA-N N,N-dimethylhydroxylamine;hydron;chloride Chemical compound Cl.CN(C)O HWWVAHCWJLGKLW-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-hydroxy-Succinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101700080605 NUC1 Proteins 0.000 description 1
- 101700084505 Nach Proteins 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 208000009905 Neurofibromatosis Diseases 0.000 description 1
- 210000000715 Neuromuscular Junction Anatomy 0.000 description 1
- 240000008962 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229960002748 Norepinephrine Drugs 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- PZWHACKIWMFOJJ-QMMMGPOBSA-N OC[C@@H](C=1C=NC(=CC=1)C)[NH-] Chemical compound OC[C@@H](C=1C=NC(=CC=1)C)[NH-] PZWHACKIWMFOJJ-QMMMGPOBSA-N 0.000 description 1
- ANFBYMZKNFPMLI-ZETCQYMHSA-N OC[C@@H](C=1C=NC(=CC=1)OC)[NH-] Chemical compound OC[C@@H](C=1C=NC(=CC=1)OC)[NH-] ANFBYMZKNFPMLI-ZETCQYMHSA-N 0.000 description 1
- 229940096717 Pamine Drugs 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000146313 Parnassius apollo Species 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229960003975 Potassium Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N Pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N Quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 102100004163 SLURP1 Human genes 0.000 description 1
- 101710005464 SLURP1 Proteins 0.000 description 1
- RXLOZRCLQMJJLC-UHFFFAOYSA-N SSR-180,711 Chemical compound C1=CC(Br)=CC=C1OC(=O)N1C(CC2)CCN2CC1 RXLOZRCLQMJJLC-UHFFFAOYSA-N 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 229940091252 Sodium supplements Drugs 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 210000003523 Substantia Nigra Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 102100000191 TRIM32 Human genes 0.000 description 1
- 101710021262 TRIM32 Proteins 0.000 description 1
- CESUXLKAADQNTB-UHFFFAOYSA-N Tert-Butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N Tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 206010044126 Tourette's disease Diseases 0.000 description 1
- 210000004515 Ventral Tegmental Area Anatomy 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- SRUIBJVUBBOHHY-UHFFFAOYSA-N [2H-benzotriazol-4-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CN(C)C(=[N+](C)C)OC1=CC=CC2=C1N=NN2 SRUIBJVUBBOHHY-UHFFFAOYSA-N 0.000 description 1
- CWTUREABAILGIK-UHFFFAOYSA-L [Li+].[Cl-].[Cl-].CC(C)[Mg+] Chemical compound [Li+].[Cl-].[Cl-].CC(C)[Mg+] CWTUREABAILGIK-UHFFFAOYSA-L 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical group C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- UQYZFNUUOSSNKT-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 UQYZFNUUOSSNKT-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229960002734 amfetamine Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 229940095076 benzaldehyde Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- HGXJOXHYPGNVNK-UHFFFAOYSA-N butane;ethenoxyethane;tin Chemical compound CCCC[Sn](CCCC)(CCCC)C(=C)OCC HGXJOXHYPGNVNK-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003292 diminished Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000002964 excitative Effects 0.000 description 1
- 239000000928 excitatory amino acid agonist Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 201000010770 muscular disease Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101700006494 nucA Proteins 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- CELWCAITJAEQNL-UHFFFAOYSA-N oxan-2-ol Chemical compound OC1CCCCO1 CELWCAITJAEQNL-UHFFFAOYSA-N 0.000 description 1
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 201000008125 pain agnosia Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229960003357 pamabrom Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 201000007188 pervasive developmental disease Diseases 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000001376 precipitating Effects 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003405 preventing Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- SVOOVMQUISJERI-UHFFFAOYSA-K rhodium(3+);triacetate Chemical class [Rh+3].CC([O-])=O.CC([O-])=O.CC([O-])=O SVOOVMQUISJERI-UHFFFAOYSA-K 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NFEGNISFSSLEGU-UHFFFAOYSA-N tert-butyl 2-diethoxyphosphorylacetate Chemical compound CCOP(=O)(OCC)CC(=O)OC(C)(C)C NFEGNISFSSLEGU-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- AHDDRJBFJBDEPW-DTWKUNHWSA-N trans-2-Phenylcyclopropanecarboxylic acid Chemical compound OC(=O)[C@@H]1C[C@H]1C1=CC=CC=C1 AHDDRJBFJBDEPW-DTWKUNHWSA-N 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/647—One oxygen atom attached in position 2 or 6 and having in the molecule an acyl radical containing a saturated three-membered ring, e.g. chrysanthemumic acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Disclosed herein are compounds of formula (I) where the substituents are as defined herein, compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine ?7 receptor. etylcholine ?7 receptor.
Description
[Annotation] sak
TITLE
POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC CHOLINE RECEPTOR
FIELD OF THE ION
The present invention relates to compounds useful in therapy, to compositions com-
prising said compounds, and to methods of treating diseases sing administration of
said compounds. The compounds referred to are positive a||osteric modulators (PAMs) of the
nicotinic acetylcholine o7 or.
BACKGROUND OF THE INVENTION
Nicotinic acetylcholine receptors (nAChRs) belong to the super family of ligand gated
ionic ls, and gate the flow of cations ing calcium. The nAChRs are endogenously
activated by acetylcholine (ACh) and can be divided into nicotinic receptors of the neuromus-
cularjunction and neuronal nicotinic receptors (NNRs). The NNRs are widely expressed
throughout the central nervous system (CNS) and the peripheral nervous system (PNS). The
NNRs have been suggested to play an important role in CNS function by modulating the re-
lease of many neurotransmitters, for example, ACh, norepinephrine, dopamine, serotonin,
and GABA, among others, resulting in a wide range of physiological effects.
Seventeen subunits of nAChRs have been reported to date, which are identified as
012-0110, , v, 6 and a. From these subunits, nine ts, (12 through (17 and [32 through
[34, prominently exist in the mammalian brain. Many functionally distinct nAChR xes
exist, for example five (17 subunits can form a receptor as a ric functional
pentamer or combinations of different subunits can form heteromeric receptors such as (1482
and (1384 receptors (Gotti, C. et al., Prog. iol., 2004, 74: 363-396;
Gotti, C. et al., Biochemical Pharmacology, 2009, 78: 703—71 1)
The homomeric d7 receptor is one of the most abundant NNRs, along with (1482 re-
ceptors, in the brain, wherein it is heavily expressed in the hippocampus, cortex, ic nu-
clei, ventral tegmental area and substantia nigra (Broad, L. M. et al., Drugs of the Future,
2007, 32(2): 161-170, Poorthuis RB, Biochem Pharmacol. 2009, 1;78(7):668—76).
The role of (17 NNR in neuronal signalling has been actively igated. The (17
NNRs have been demonstrated to regulate interneuron excitability and modulate the e
of excitatory as well as inhibitory neurotransmitters. In addition, (17 NNRs have been reported
to be involved in neuroprotective effects in experimental models of cellular damage (Shimo-
hama, 8., Biol Pharm Bull. 2009, 32(3):332-6).
[Annotation] sak
Studies have shown that (17 subunits, when expressed recombinant in-vitro, activate and de-
sensitize rapidly, and exhibit relatively higher calcium permeability compared to other NNR
combinations (Papke, R.L. et al., J col Exp Ther. 2009, 329(2):791-807).
The NNRs, in l, are involved in various cognitive functions, such as ng,
memory and ion, and therefore in CNS ers, i.e., Alzheimer's disease (AD),
Parkinson's disease (PD), attention t hyperactivity disorder (ADHD), Tourette's syn-
drome, schizophrenia, bipolar er, pain and tobacco dependence (Keller, J. J. et al., Be-
hav. Brain Res. 2005, 162: ; Haydar, S.N. et al., Curr Top Med Chem. 2010;10(2):144-
52).
The G7 NNRs in ular, have also been linked to cognitive disorders including, for
example, ADHD, autism um disorders, AD, mild cognitive impairment (MCI), age asso-
ciated memory impairment (AAMI) senile dementia, frontotemporal lobar degeneration, HIV
associated dementia (HAD), HIV associated cognitive impairment (HIV-Cl), Pick's disease,
ia associated with Lewy , cognitive impairment associated with Multiple Sclero-
sis, Vascular Dementia, cognitive impairment in Epilepsy, cognitive impairment associated
with fragile X, cognitive impairment associated with Friedreich’s Ataxia, and dementia associ-
ated with Down's syndrome, as well as cognitive impairment associated with schizophrenia.
In addition, s have been shown to be involved in the neuroprotective effects of nico-
tine both in vitro (Jonnala, R. B. et al., J. Neurosci. Res., 2001, 66: 565- 572) and in vivo
(Shimohama, 8., Brain Res., 1998, 779: 359-363) as well as in pain signalling. More particularly
, neurodegeneration underlies l progressive CNS disorders, including, but not lim-
ited to, AD, PD, amyotrophic lateral sclerosis, Huntington's disease, dementia with Lewy bod-
ies, as well as diminished CNS function resulting from traumatic brain injury. For example, the
impaired function of (17 NNRs by beta-amyloid peptides linked to AD has been implicated as a
key factor in development of the cognitive deficits associated with the disease (Liu, Q.-S., et
al., PNAS, 2001,98: 4734-4739). Thus, modulating the ty of (17 NNRs demonstrates
promising potential to prevent or treat a variety of diseases indicated above, such as AD,
other ias, other neurodegenerative diseases, schizophrenia and neurodegeneration,
with an underlying ogy that involves cognitive function including, for example, aspects
of learning, memory, and attention (Thomsen, M.S. et al., Curr Pharm Des. 2010
Jan;16(3):323-43; Olincy, A. et al., Arch Gen Psychiatry. 2006, 63(6):630-8; Deutsch, S.|.,
Clin Neuropharmacol. 2010, 33(3):114-20; Feuerbach, D., Neuropharmacology. 2009, 56(1):
The NNR ligands, including (17 ligands, have also been implicated in weight control,
diabetis inflammation, obsessive-compulsive disorder (OCD), angiogenesis and as potential
analgesics (Marrero, M.B. et al., J. Pharmacol. Exp. Ther. 2010, 332(1):173-80; Vincler, M.,
[Annotation] sak
Exp. nvest. Drugs, 2005, 14 (10): 1191-1 198; Rosas-Ballina, M., J. Intern Med. 2009
265(6):663-79; Arias, H.R., Int. J. Biochem. Cell Biol. 2009, 41(7):1441-51; Tizabi, Y., Biol
Psychiatry. 2002, 51 (2):164-71).
Nicotine is known to enhance ion and cognitive performance, reduced anxiety,
enhanced sensory gating, and analgesia and neuroprotective effects when administered.
Such effects are mediated by the non-selective effect of nicotine at multiple nicotinic receptor
subtypes. However, nicotine also exerts adverse events, such as cardiovascular and gastro-
intestinal problems (Karaconji, |.B. et al., Arh Hig Rada Toksikol. 2005, 363-71). Con-
sequently, there is a need to identify subtype-selective compounds that retain the beneficial
effects of nicotine, or an NNR ligand, while eliminating or decreasing adverse effects.
Examples of ed NNR ligands are or? NNR agonists, such as DMXB-A,
SSR180711 and ABT-107, which have shown some beneficial effects on cognitive processing
both in rodents and humans (H312: 1213-22; , A. et al., Arch Gen Psychiatry. 2006
63(6):630-8; Pichat, P., et al., Neuropsychopharmaco/ogy. 2007 32(1):17-34; Bitner, R.S., J
Pharmacol Exp Ther. 2010 1;334(3):875-86). In addition, modulation of or? NNRs have been
ed to improve ve ms in patients with phrenia (Freedman, R. et al.,
Am J Psychiatry. 2008 :1040-7).
Despite the beneficial effects of NNR ligands, it remains uncertain whether chronic
treatment with agonists affecting NNRs may provide suboptimal benefit due to sustained acti-
vation and desensitization of the NNRs, in particular the o7 NNR subtype. In contrast to ago-
nists, administering a positive eric modulator (PAM) can reinforce endogenous choliner-
gic ission without directly stimulating the target receptor. Nicotinic PAMs can selec-
tively modulate the activity of ACh at NNRs, preserving the activation and deactivation kinet-
ics of the receptor. Accordingly, o7 NNR-selective PAMs have emerged (Faghih, R., Recent
Pat CNS Drug Discov. 2007, 2(2):99—106).
uently, it would be beneficial to increase or? NNR on by enhancing the ef-
fect of the nous neurotransmitter acetvlcholine via PAMs. This could reinforce the en-
dogenous cholinergic neurotransmission without directly activating o7 NNRs, like agonists.
Indeed, PAMs for ing channel activity have been proven clinically successful for
GABAa receptors where benzodiazepines and barbiturates, behave as PAMs acting at dis-
tinct sites (Hevers, W. et al., Mol. Neurobiol., 1998, 18: 35-86).
To date, only a few NNR PAMs are known, such as 5-hydroxyindole (5-Hl), ivermec-
tin, galantamine, and SLURP-1, a peptide derived from acetylcholinesterase (AChE). Gen-
, a kinase inhibitor was also reported to increase or? responses. PNU-120596, a urea
derivative, was reported to increase the potency of ACh as well as improve auditory gating
ts induced by amphetamine in rats. Also, NS1738, JNJ-1930942 and compound 6 have
ation] sak
been reported to potentiate the response of ACh and exert beneficial effect in experimental
models of sensory and cognitive processing in rodents. Other NNR PAMs include derivatives
of quinuclidine, indole, benzopyrazole, le, and benzoisothiazoles (Hurst, R. S. et al., J.
ci. 2005, 25: 4396-4405; Faghih, R., Recent Pat CNS Drug Discov. 2007, 2(2):99—106;
Timmermann, D.B., J. Pharmacol. Exp. Ther. 2007, 323(1):294-307; Ng, H.J. et al., Proc.
Natl. Acad. Sci. U SA. 2007, 8;104(19):8059—64; Dinklo, T., J. Pharmacol. Exp. Ther. 2011,
336(2):560-74.).
recites compounds of the overall ure
Ar1\fl/N NZ
R1 R2
which compounds are said to be PAMs of the o7 NNR.
The (17 NNR PAMs presently known generally trate weak activity, have a
range of non-specific effects, or can only e limited access to the central nervous sys-
tem where (17 NNRs are abundantly expressed. Accordingly, it would be beneficial to identify
and provide new PAM compounds of (17 NNRs and compositions for treating diseases and
disorders wherein o7 NNRs are involved. It would further be particularly beneficial if such
compounds can e improved efficacy of treatment while reducing adverse effects asso-
ciated with nds ing neuronal nicotinic receptors by selectively modulating o7
NNRs.
s compounds of the overall structure
R2 0
Y /
(R)v N (Ci)q-(O)r-Ar
p R5
R1 2/ ( R3)w
as calcium or sodium channel blockers. Compound examples disclosed in
are not intended to be included in the present invention.
Particularly the compounds (1 2-Phenyl-cyclopropanecarboxylic acid {(S)—1-[5-
(2,2,2-trifluoro-ethoxy)—pyridinyl]—ethy|}-amide, (1 S,2S)(2-Chlorofluoro-phenyl)-
cyclopropanecarboxylic acid {(S)—1-[5-(2,2,2-trifluoro-ethoxy)—pyridinyl]-ethyl}-amide and
(1 S,2S)(2-F|uoromethoxy-phenyl)-cyc|opropanecarboxylic acid {(S)—1-[5-(2,2,2-trifluoroethoxy
)-pyridinyl]-ethyl}-amide are disclosed in are disclaimed from the
present invention
[Annotation] sak
SUMMARY OF THE INVENTION
The objective of the t invention is to provide compounds that are positive allos-
teric modulators (PAMs) of the nicotinic acetylcholine receptor subtype 017.
The compounds of the present invention are defined by formula [I] below:
N \As
H I
/ [L9
wherein R1, R2, R3, R4 and R5 are selected independently of each other from H, C1-5a|ky|,
02-5alkenyl, Cz_6alkynyl, C1_5alkoxy, cyano and halogen, wherein said C1_6alkyl, 02-5alkenyl and
Cz_6alkynyl is optionally substituted with one or more substituents independently selected from
chlorine and fluorine;
R6 is selected from C1-6alkyl, 02-6alkenyl, kynyl and C1_6alkoxy, wherein said kyl,
Cz_6alkenyl and Cz_6alkynyl is ally substituted with one or more substituents independ-
ently selected from hydroxy, C1-5a|koxy and fluorine;
A7 is C-R7 or N, A8 is C-R8 or N and A9 is C-R9 or N, provided that at least one of A7, A8 or
and 9 is N and no more than two of A7, A8 and A9 is N;
R7, R8, R9, R10 and R11 are selected independently of each other from H, C1_6alkyl, CZ-
ealkenyl, Cz_6alkynyl, C1_6alkoxy, cyano, NR12R13, C1-5a|kylsulfony|, halogen and OR14,
wherein said C1-5alky|, 02-5alkenyl, Cz_6alkynyl or C1-5a|koxy is optionally tuted with one
or more substituents ed from chlorine, fluorine, koxy, cyano and NR12R13;
R12 and R13 independently represent en, C1_6alkyl, 02-5alkenyl and Cz_6alkynyl;
R14 represents a clic saturated ring moiety having 4-6 ring atoms wherein one of said
ring atoms is O and the others are C;
or R9 and R10 may be linked together to form the moiety indicated below
O\l-/]n
wherein n is 1, 2 or 3;
[Annotation] sak
and pharmaceutically acceptable salts thereof;
with the proviso that the nd of formula [I] is other than
(1 S,2S)Phenyl-cyclopropanecarboxylic acid {(S)—1-[5-(2,2,2-trifluoro-ethoxy)—pyridinyl]—
ethy|}-amide;
(1 S,2S)(2-Chlorofluoro-phenyl)-cyc|opropanecarboxylic acid -[5-(2,2,2-trifluoro-
ethoxy)—pyridinyl]-ethyl}-amide;
(1 S,2S)(2-F|uoromethoxy-phenyl)-cyc|opropanecarboxylic acid {(S)—1-[5-(2,2,2-trifluoro-
ethoxy)—pyridinyl]-ethyl}-amide.
In one embodiment, the invention s to a compound ing to formula [I], and
pharmaceutically acceptable salts thereof, for use as a medicament.
In one embodiment, the invention s to a compound according to a [I], and
pharmaceutically acceptable salts thereof, for use in therapy.
In one embodiment, the invention relates to a compound according to formula [I], and
pharmaceutically acceptable salts thereof, for use in the treatment of a disease or disorder
selected from Psychosis; Schizophrenia; cognitive disorders; ive impairment associated
with schizophrenia; Attention Deficit Hyperactivity Disorder (ADHD); autism spectrum disor-
ders, Alzheimer’s disease (AD); mild cognitive impairment (MCI); age associated memory im-
pairment (AAMI); senile dementia; AIDS dementia; Pick's disease; dementia ated with
Lewy bodies; dementia associated with Down's syndrome; Huntington's Disease; Parkinson’s
disease (PD); obsessive-compulsive disorder (OCD); traumatic brain injury; epilepsy; post-
traumatic stress; Wernicke-Korsakoff syndrome (WKS); post-traumatic amnesia; cognitive
deficits associated with depression; diabetes, weight control, inflammatory disorders, reduced
angiogenesis; amyotrophic lateral sclerosis and pain.
In one ment, the invention relates to a pharmaceutical composition comprising
a compound according to formula [I] and pharmaceutically acceptable salts f, and one
or more pharmaceutically acceptable carrier or excipient.
In one embodiment, the invention relates to a kit comprising a compound ing to
formula [I], and pharmaceutically acceptable salts thereof, together with a nd selected
from the list consisting of acetylcholinesterase inhibitors; glutamate or antagonists; do-
pamine transport inhibitors; noradrenalin transport inhibitors; D2 nists; D2 l ago-
nists; PDE10 antagonists; 5-HT2A antagonists; 5-HT6 antagonists; KCNQ antagonists; lith-
ium; sodium l blockers and GABA signaling enhancers.
In one embodiment, the invention relates to a method for the treatment of a disease or
disorder selected from Psychosis; Schizophrenia; cognitive disorders; cognitive impairment
associated with schizophrenia; Attention Deficit Hyperactivity er (ADHD); autism spec-
trum disorders, Alzheimer’s disease (AD); mild cognitive impairment (MCI); age associated
[Annotation] sak
memory impairment (AAMI); senile dementia; AIDS dementia; Pick's disease; dementia asso-
ciated with Lewy bodies; dementia associated with Down's syndrome; Huntington's Disease;
Parkinson’s disease (PD); ive-compulsive disorder (OCD); traumatic brain injury; epi-
lepsy; raumatic stress; Wernicke-Korsakoff syndrome (WKS); post-traumatic amnesia;
cognitive deficits associated with depression; es, weight control, inflammatory disor-
ders, reduced angiogenesis; amyotrophic lateral sclerosis and pain, which method comprises
the administration of a therapeutically effective amount of a compound according to formula
[I], and pharmaceutically acceptable salts thereof.
In one embodiment, the invention relates to the use of a compound according to for-
mula [I], and pharmaceutically acceptable salts thereof, for the manufacture of a medicament
for the ent of a disease or er selected from Psychosis; Schizophrenia; cognitive
disorders; cognitive impairment associated with schizophrenia; Attention t Hyperactivity
Disorder (ADHD); autism spectrum disorders, Alzheimer’s disease (AD); mild cognitive im-
pairment (MCI); age ated memory impairment (AAMI); senile dementia; AIDS demen-
tia; Pick's e; dementia associated with Lewy bodies; dementia associated with Down's
syndrome; Huntington's Disease; Parkinson’s disease (PD); obsessive-compulsive disorder
(OCD); traumatic brain injury; sy; post-traumatic stress; Wernicke-Korsakoff syndrome
(WKS); post-traumatic amnesia; ive deficits associated with depression; diabetes,
weight control, inflammatory disorders, reduced angiogenesis; amyotrophic lateral sclerosis
and pain.
Definitions
In the present context, “optionally substituted” means that the indicated moiety may or
may not be substituted, and when substituted is mono-, di-, or tri-substituted, such as with 1,
2 or 3 substituents. In some instances, the substituent is independently selected from the
group ting of C1_6alkyl, 02-5alkenyl, kynyl, phenyl, C1_5alkoxy, hydroxy and halo-
gen. It is understood that where no substituents are indicated for an “optionally tuted”
moiety, then the position is held by a hydrogen atom.
In the present context, “alkyl” is intended to indicate a straight, branched and/or cyclic
saturated hydrocarbon. In ular “C1-6a|kyl” is intended to indicate such hydrocarbon hav-
ing 1, 2, 3, 4, 5 or 6 carbon atoms. Examples of C1_6alkyl include methyl, ethyl, propyl, butyl,
pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclopropyl, 2-methylpropyl
and tert-butyl. Examples of substituted C1-5a|ky| include e.g. fluoromethyl and hy-
droxymethyl.
In the present context, yl” is intended to te a omatic, straight,
branched and/or cyclic arbon comprising at least one carbon-carbon double bond. In
ation] sak
particular “02-6alkenyl” is intended to indicate such hydrocarbon having 2, 3, 4, 5 or 6 carbon
atoms. Examples of 02-5alkenyl e ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, nyl
and 3-butenyl and cyclohexenyl.
In the present t, “alkynyl” is intended to indicate a non-aromatic, straight,
branched and/or cyclic hydrocarbon comprising at least one carbon-carbon triple bond and
optionally also one or more carbon-carbon double bonds. In particular “02-6alkynyl” is in-
tended to indicate such hydrocarbon having 2, 3, 4, 5 or 6 carbon atoms. Examples of CZ-
ealkynyl include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl and 5-but
nyl.
In the present context, “hydroxy” is intended to indicate —OH.
In the present context, “alkoxy” is intended to indicate a moiety of the formula —OR’,
wherein R’ indicates alkyl as defined above. In particular “C1-6a|koxy” is intended to indicate
such moiety wherein the alkyl part has 1, 2, 3, 4, 5 or 6 carbon atoms. es of “C1-
salkoxy” include methoxy, ethoxy, n-butoxy and tert-butoxy.
In the present context, “alkylsulfonyl” is intended to indicate —S(O)2alkyl In particular
C1-5alkylsulfonyl is intended to indicate such a moiety wherein the alkyl part has 1, 2, 3, 4, 5
or 6 carbon atoms. Particular mention is made of methylsulfonyl.
In the present context, a “monocyclic moiety” is ed to cyclic moiety comprising
only one ring, said cyclic moiety can be saturated or unsaturated.
In the present context, the terms “halo” and “halogen” are used interchangeably and
refer to fluorine, ne, bromine or iodine.
In the t context, the term “cyano” indicates the group -CEN, which consists of a
carbon atom triple-bonded to a nitrogen atom.
In the present context, ”ring atom” is intended to indicate the atoms constituting a ring,
and ring atoms are selected from C, N, O and 8. As an example, benzene and e both
have 6 carbons as ring atoms whereas pyridine has 5 carbons and 1 nitrogen as ring atoms.
In the t context, “heteroatom” means a nitrogen, oxygen or sulfur atom.
In the present context, “deuterium” indicates the atomic isotope of hydrogen consisting
of one proton and one neutron in its nucleus, and thus having an approximate weight of two
(2). Deuterium is represented as D, d or 2H. An example of a substituent comprising deute-
rium is -d3)-ethoxy wherein three of the hydrogens in ethoxy are the 2H isotopes.
In the present context, “enantiomeric excess” represents the % excess of a compound
in a mixture of compound enantiomers. If for example an omeric excess is 90% then
the ratio of the compound to its enantiomer is 95:5 and if an enantiomeric excess is 95% then
the ratio of the nd to its enantiomer is 97.525 Likewise, “diastereomeric ”
represents % excess of a compound in a mixture of compound diastereomers.
[Annotation] sak
In the t context, pharmaceutically acceptable salts include pharmaceutically
acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alky-
lated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic
acids.
es of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic,
phosphoric, sulfuric, ic, nitric acids and the like.
Examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroace-
tic, nic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, esulfonic,
maleic, malic, malonic, mandelic, oxalic, picric, c, salicylic, succinic, methane sulfonic,
ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic,
citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesul-
fonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8—halotheophyllines, for
example 8—bromotheophylline and the like. Further examples of ceutical acceptable
inorganic or c acid addition salts include the pharmaceutically acceptable salts listed in
Berge, SM. et al., J. Pharm. Sci. 1977,66,2, which is incorporated herein by reference.
es of metal salts include lithium, sodium, potassium, magnesium salts and the
like.
Examples of ammonium and alkylated ammonium salts include ammonium, methyl-,
dimethyl-, trimethyl-, ethyl-, hydroxyethyl-, l-, n-butyl-, sec-butyl-, tert-butyl-, tetrame-
thylammonium salts and the like.
In the present context, pharmaceutical carriers include inert solid diluents or fillers,
sterile aqueous solutions and various organic solvents. es of solid carriers include lac-
tose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate,
stearic acid and lower alkyl ethers of cellulose. Examples of liquid carriers include, but are not
limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid , poly-
oxyethylene and water. Similarly, the carrier may include any sustained release material
known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a
wax.
In the present context, the term "therapeutically ive " of a nd
means an amount sufficient to cure, alleviate or partially arrest the al manifestations of a
given disease and its complications in a eutic intervention comprising the administra-
tion of said compound. An amount adequate to accomplish this is defined as "therapeutically
effective amount". Effective amounts for each purpose will depend on the severity of the dis-
ease or injury as well as the weight and l state of the subject. It will be understood that
determining an appropriate dosage may be achieved using routine experimentation, by con-
[Annotation] sak
structing a matrix of values and testing different points in the matrix, which is all within the or-
dinary skills of a trained ian.
In the present context, the term ment" and "treating" means the management
and care of a patient for the purpose of combating a condition, such as a disease or a disor-
der. The term is intended to include the full spectrum of treatments for a given condition from
which the patient is ing, such as administration of the active compound to alleviate the
symptoms or complications, to delay the progression of the disease, disorder or condition, to
alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease,
er or condition as well as to prevent the condition, wherein prevention is to be under-
stood as the ment and care of a patient for the purpose of combating the e,
condition, or disorder and includes the administration of the active compounds to prevent the
onset of the symptoms or complications. eless, prophylactic (preventive) and thera-
peutic (curative) treatments are two separate aspects of the present invention. The patient to
be d is ably a , in particular a human being.
In the present context, the term "cognitive disorders" is intended to indicate disorders
characterized by abnormalities in aspects of perception, problem solving, language, learning,
working memory, memory, social recognition, attention and pre-attentional processing, such
as by not limited to Attention t Hyperactivity Disorder (ADHD), autism spectrum disor-
ders, Alzheimer’s e (AD), mild cognitive impairment (MCI), age associated memory im-
pairment (AAMI), senile dementia, vascular dementia, frontotemporal lobe dementia, Pick's
disease, dementia ated with Lewy bodies, and dementia associated with Down's syn-
drome, cognitive impairment associated with Multiple Sclerosis, cognitive impairment in epi-
lepsy, cognitive ment associated with fragile X, cognitive impairment associated with
neurofibromatosis, cognitive impairment associated with Friedreich’s Ataxia, progressive su-
pranuclear palsy (PSP), HIV associated dementia (HAD), HIV associated cognitive impair-
ment (HIV-Cl), gton's Disease, Parkinson’s e (PD), obsessive-compulsive dis-
order (OCD), traumatic brain injury, epilepsy, post-traumatic stress, Wernicke-Korsakoff syn-
drome (WKS), post-traumatic amnesia, cognitive deficits associated with depression as well
as ive impairment associated with schizophrenia.
The cognitive enhancing properties of a compound can be assessed eg. by the atten-
tional set-shifting paradigm which is an animal model allowing assessment of executive func-
tioning via intra-dimensional (lD) versus extra-dimensional (ED) shift discrimination ng.
The study can be performed by testing whether the compound is attenuating tional per-
formance impairment” induced by subchronic PCP administration in rats as described by
Rodefer, J.S. et al., Eur. J. Neurosci. 2005, 21:1070-1076.
[Annotation] sak
In the present t, the term "autism spectrum disorders" is intended to te
disorders characterized by widespread alities of social interactions and verbal and
non-verbal communication, as well as restricted interests, repetitive behavior and attention,
such as by not limited to autism, Asperger syndrome, Pervasive Developmental Disorder Not
Otherwise Specified (PDD-NOS), Rett syndrome, Angelmann syndrome, e X, DiGeorge
syndrome and Childhood Disintegrative Disorder.
In the present context, the term "inflammatory disorders” is intended to indicate disor-
ders characterized by abnormalities in the immune system such as by not limited to, ic
reactions and myopathies resulting in abnormal inflammation as well as non-immune
diseases with etiological origins in inflammatory ses are thought to include but not be
limited to cancer, atherosclerosis, osteoarthritis, rheumatoid arthritis and ischaemic heart
disease.
DETAILED DESCRIPTION OF THE INVENTION
The present inventors have found that certain new compounds are ve allosteric
modulators (PAMs) of NNRs, and as such may be used in the treatment of various ers.
PAMs of NNRs may be dosed in combination with other drugs in order to achieve
more efficacious treatment in certain patient populations. An (17 NNR PAM may act synergis-
tically with another drug, this has been described in animals for the combination of com-
pounds affecting nicotinic receptors, including (17 NNRs and D2 antagonism (Wiker, 0., Int. J.
Neuropsychopharmacol. 2008, 11(6):845-50).
Thus, compounds of the present invention may be useful treatment in the combination
with another drug e.g. selected from acetylcholinesterase inhibitors, glutamate receptor an-
tagonists, dopamine transport inhibitors, noradrenalin transport inhibitors, D2 antagonists, D2
partial agonists, PDE10 nists, 5-HT2A antagonists, 5-HT6 antagonists and KCNQ an-
tagonists, lithium, sodium channel blockers, GABA signalling enhancers.
In one ment, compounds of the present invention are used for ent of pa-
tients who are already in treatment with another drug ed from the list above. In one em-
bodiment, compounds of the present invention are adapted for administration simultaneous
with said other drug. In one embodiment compounds of the present invention are d for
administration sequentially with said other drug. In one ment, compounds of the pre-
sent invention are used as the sole medicament in treatment of a patient. In one embodiment,
compounds of the present ion are used for treatment of patients who are not already in
treatment with r drug selected from the list above.
Embodiments according to the invention
[Annotation] sak
In the following, embodiments of the invention are disclosed. The first embodiment is
denoted E1, the second embodiment is denoted E2 and so forth.
E1. A compound according to formula [I]
N \As
H I
/ [L9
wherein R1, R2, R3, R4 and R5 are selected independently of each other from H, C1-5alkyl,
02-5alkenyl, Cz_6alkynyl, C1_5alkoxy, cyano and halogen, wherein said C1_6alkyl, 02-5alkenyl and
Cz_6alkynyl is optionally substituted with one or more substituents independently selected from
chlorine and fluorine;
R6 is selected from C1-6a|ky|, Cz_6a|keny|, Cz_6a|kyny| and C1_6alkoxy, wherein said C1_6a|ky|,
keny| and Cz_6alkynyl is optionally substituted with one or more substituents independ-
ently selected from hydroxy, C1-5alkoxy and ne;
A7 is C-R7 or N, A8 is C-R8 or N and A9 is C-R9 or N, ed that at least one of A7, A8 or
and 9 is N and no more than two of A7, A8 and A9 is N;
R7, R8, R9, R10 and R11 are selected independently of each other from H, C1_6alkyl, CZ-
ealkenyl, Cz_6alkynyl, C1_6alkoxy, cyano, NR12R13, C1-5alkylsulfonyl, n and OR14,
wherein said C1-5alkyl, 02-5alkenyl, Cz_6alkynyl or C1_6alkoxy is optionally substituted with one
or more substituents selected from chlorine, ne, C1_6alkoxy, cyano and NR12R13;
R12 and R13 independently represent en, C1_6alkyl, 02-5alkenyl and Cz_6alkynyl;
R14 represents a monocyclic ted ring moiety having 4-6 ring atoms n one of said
ring atoms is O and the others are C;
or R9 and R10 may be linked together to form the moiety indicated below
O\l-/]n
wherein n is 1, 2 or 3;
and pharmaceutically acceptable salts thereof;
[Annotation] sak
with the proviso that the compound of formula [I] is other than
(1 S,28)Phenyl-cyclopropanecarboxylic acid {(S)—1-[5-(2,2,2-trifluoro-ethoxy)—pyridinyl]—
ethy|}-amide;
(1 S,28)(2-Chlorofluoro-phenyl)-cyclopropanecarboxylic acid {(S)—1-[5-(2,2,2-trifluoroethoxy
)—pyridinyl]-ethyl}-amide;
(1 S,28)(2-F|uoromethoxy-phenyl)-cyclopropanecarboxylic acid {(S)—1-[5-(2,2,2-trifluoro-
ethoxy)—pyridinyl]-ethyl}-amide.
E2. The compound ing to embodiment 1, wherein R1, R2, R3, R4 and R5 are se-
lected independently of each other from H, methyl, fluorine and chlorine;
R6 is selected from methyl, hydroxymethyl, methoxymethyl and fluoromethyl;
R7, R8, R9, R10 and R11 are selected independently of each other from H, C1_4alkyl, C1-
4alkoxy, cyano, -N(CH3)2, methylsulfonyl, fluorine, chlorine and OR14, n said C1_4alkyl
or C1.4a|koxy is ally substituted with one or more substituents selected from fluorine, C1-
4a|koxy and cyano;
R14 represents a monocyclic saturated ring moiety having 4-6 ring atoms wherein one of said
ring atoms is O and the others are C;
or R9 and R10 may be linked together to form the moiety indicated below
O\l-/]n
wherein n is 1 or 2.
E3. The compound ing to any of ments 1-2, n R1, R2, R3, R4 and R5
are selected independently of each other from H, methyl, fluorine and chlorine.
E4. The compound according to any of embodiments 1-3, wherein four or more of R1, R2,
R3, R4 and R5 are H.
E5. The compound according to embodiment 4, wherein all of R1, R2, R3, R4 and R5 are
E6. The compound according to any of embodiments 1-5, wherein R6 is selected from
methyl , hydroxymethyl, methoxymethyl and fluoromethyl.
[Annotation] sak
E7. The compound according to ment 6, wherein R6 is methyl.
E8. The compound according to embodiment 6, wherein R6 is hydroxymethyl.
E9. The compound according to ment 6, wherein R6 is ymethyl.
E10. The compound ing to embodiment 6, wherein R6 is fluoromethyl.
E11. The compound according to any of ments 1-10, wherein R7, R8, R9, R10 and
R11 are selected independently of each other from H, C1_4alkyl, C1_4alkoxy, cyano, -N(CH3)2,
methylsulfonyl, fluorine, chlorine and OR14, wherein said C1_4alkyl or C1_4alkoxy is optionally
substituted with one or more substituents selected from fluorine, koxy and cyano;
R14 represents a monocyclic saturated ring moiety having 4-6 ring atoms wherein one of said
ring atoms is O and the others are C;
or R9 and R10 may be linked together to form the moiety indicated below
O\l-/]n
wherein n is 1 or 2;
E12. The compound according to any of embodiments 1 and 3-11, wherein R7, R8, R9,
R10 and R11 are selected independently from H, C1_6alkyl, 02-5alkenyl, 02.6alkynyl, C1_6alkoxy,
cyano or halogen, wherein said C1_6alkyl, 02-6alkenyl, 02-6alkynyl or C1_6alkoxy is optionally
substituted with one or more substituents selected from fluorine, C1.6alkoxy and cyano.
E13. The compound according to any of embodiments 1-12, wherein R7, R8, R9, R10 and
R11 are selected independently from H, C1_4alkyl, Cz_4alkenyl, Cz_4alkynyl, koxy, cyano
and halogen, wherein said C1_4alkyl, Cz_4alkenyl, Cz_4alkynyl or koxy is optionally substi-
tuted with one or more tuents selected from fluorine and C1_4alkoxy.
E14. The compound according to any of embodiments 1-13, wherein one or more of the
hydrogen atoms are represented by deuterium.
E15. The compound according to embodiment 14, wherein one or more of the hydrogen
atoms in R7, R8, R9, R10 and R11 are represented by deuterium.
ation] sak
E16. The compound according to any of embodiments 14-15, wherein at least about 85%
of the compound has a deuterium atom at each position designated as ium, and any
atom not designated as deuterium is present at about its natural isotopic abundance.
E17. The compound according to embodiment 16, wherein at least about 90% of the com-
pound has a deuterium atom at each position designated as deuterium, and any atom not
designated as deuterium is present at about its l isotopic abundance.
E18. The compound according to any of embodiments 1-17, wherein no more than one of
A7, A8 or A9 is N.
E19. The nd according to any of embodiments 1-18, wherein A7 is N, A8 is C-R8
and A9 is C-R9.
E20. The compound according to embodiment 19, wherein R8, R10 and R11 all represent
E21. The compound according to any of embodiments 1-18, wherein A8 is N, A7 is C-R7
and A9 is C-R9.
E22. The compound ing to embodiment 21, wherein R7, R10 and R11 all represent
E23. The compound according to any of embodiments 19-22, wherein R9 is selected from
methyl, C1_4alkoxy or cyano, n said methyl is optionally substituted with C1_4alkoxy or
one or more fluorine.
E24. The compound according to embodiment 23, wherein R9 represents koxy and
one or more of the hydrogen atoms in said C1.4alkoxy are represented by deuterium.
E25. The compound according to any of embodiments 19-22, wherein R9 is OR14, wherein
R14 represents a monocyclic saturated ring moiety having 4-6 ring atoms wherein one of said
ring atoms is O and the others are C.
[Annotation] sak
E26. The compound according to any of embodiments 1-18, wherein A9 is N, A7 is C-R7
and A8 is C-R8.
E27. The compound according to embodiment 26, wherein R7, R8 and R11 all represent H.
E28. The nd according to any of embodiments 26-27, wherein R10 is selected from
methyl, C1_4alkoxy or cyano, wherein said methyl is optionally substituted with C1_4alkoxy or
one or more fluorine.
E29. The compound according to embodiment 28, wherein R10 represents koxy and
one or more of the hydrogen atoms in said C1.4a|koxy are ented by deuterium.
E30. The compound according to any of embodiments 1-17, wherein two of A7, A8 or A9
are N.
E31. The compound according to any of embodiments 1-30 having a diastereomeric ex-
cess of at least 80% such as at least 85%, such as at least 90%, such as at least 95%.
E32. The compound according to embodiment 1 ed from
1 : (1 S, Phenyl—cyclopropanecarboxylic acid [(S)(6-isopropoxy—pyridinyl)-ethyl]—
amide;
2: (1 S, 2S)Phenyl—cyclopropanecarboxylic acid [(S)(5-methyl—pyridiny/)-ethyl]—amide;
3: (1 S, 28)Phenyl—cyclopropanecarboxylic acid [(S)(6-methoxy—pyridinyl)-ethy/]—amide;
4: (1 S, 2S)Phenyl—cyclopropanecarboxylic acid [(S)(6-methyl—pyridin-3—y/)-ethyl]—amide;
5: (1 S, 2S)-2—Phenyl—cyclopropanecarboxylic acid [(S)(6-cyano-pyridinyl)-ethyl]—amide;
6: (1 S, Phenyl—cyclopropanecarboxylic acid [(S)(6-trifluoromethyl—pyridinyl)-ethyl]-
amide;
7: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(S)(6-ethoxy-pyridin-3—y/)-ethyl]—amide;
8: (1 S, 28)Phenyl—cyclopropanecarboxylic acid [(S)(6-ethyl-pyridinyl)-ethy/]—amide;
9: (1 S, 28)Phenyl—cyclopropanecarboxylic acid [(S)(6-methoxymethyl-pyridinyl)-ethyl]—
amide;
1 0: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid {(S)-1 -[6-(2, 2, 2-trifluoro-ethoxy)-pyridin-3—
y/]-ethyl}-amide;
1 1 : (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(S)[6-(2-methoxy-ethoxy)-pyridinyl]—
-amide;
12: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(S)(2-ethoxy-pyridiny/)-ethyl]—amide;
[Annotation] sak
13: (1 S, 2S)Phenyl-cyclopropanecarboxy/ic acid ((S){6-[(S)—(tetrahydro-furanyl)oxy]-
pyridiny/}-ethyl)—amide;
14: (1 S, 2S)Phenyl-cyclopropanecarboxy/ic acid ((S){6-[(R)—(tetrahydro-furanyl)0ny-
pyridinyl}-ethyl)-amide;
: (1 S, 28)-2—Phenyl—cyclopropanecarboxy/ic acid -[1, 3]dioxo/o[4, 5-b]pyridinyl—ethyl)-
amide;
16: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(S)(2, 3-dihydro-[1, ino[2, 3-
b]pyridin- 7-y/)-ethyl]—amide;
17: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(S)(2-ethoxy-pyrimidiny/)-ethyl]—
amide;
1 8: (1 S, 2S)Phenyl-cyclopropanecarboxy/ic acid [(S)(6-chloro-pyridiny/)-ethyl]—amide;
19: (1 S, 2S)Phenyl-cyclopropanecarboxy/ic acid {(8)[6-(oxetanyloxy)—pyridinyl]—
ethyl}-amide;
: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(S)(6-cyanomethoxy-pyridinyl)—
ethy/J-amide;
21 : (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(R)hydroxy(6-propoxy-pyridiny/)-
ethy/J-amide;
22: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(R)hydroxy(6-trifluoromethyl-pyridin-
3-yl)-ethy/]—amide;
23: (1 S, 28)-2—Phenyl—cyclopropanecarboxy/ic acid -(5-cyano-pyridin-2—yl)—2—hydroxy-
ethy/J-amide;
24: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid -hydroxy(6-methoxy-pyridinyl)—
ethy/J-amide;
: (1 S, 28)-2—Phenyl—cyclopropanecarboxy/ic acid [(R)hydroxy(6-methyl—pyridinyl)—
ethy/J-amide;
26: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(R)hydroxy(6-isopropoxy-pyridin
y/)-ethy/]-amide;
27: (1 S, 2S)(3-Fluoro-phenyl)-cyclopropanecarboxy/ic acid [(R)(6-ethoxy-pyridiny/)—2—
hydroxy-ethy/]—amide;
28: (1 S, 2S)(4-Fluoro-phenyl)-cyclopropanecarboxy/ic acid [(R)(6-ethoxy-pyridiny/)—2—
hydroxy-ethy/]—amide;
29: (1 S, (3-F/uoro-phenyl)—cyclopropanecarboxy/ic acid [(R)hydroxy(6-propoxy-
pyridiny/)-ethyl]—amide;
: (1 S, 2S)-2—(4-F/uoro-phenyl)—cyclopropanecarboxy/ic acid [(R)hydroxy(6-propoxy-
pyridiny/)-ethyl]—amide;
[Annotation] sak
31 : (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(R)-1 -(6-(2, 2, 2-d3)-ethoxy-pyridin-3—yl)—2-
hydroxy-ethy/]—amide,'
32: (1 S, 2S)(3-Fluoro-phenyl)-cyclopropanecarboxy/ic acid [(R)(6-(1, 1 -d2)-ethoxy-pyridin-
3—yl)hydroxy-ethy/]—amide,'
33: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(R)(6-ethoxy-pyridin-3—y/)hydroxy-
ethy/J-amide;
34: (1 S, 2S)(4-Fluoro-phenyl)-cyclopropanecarboxy/ic acid [(R)(6-(1, 1, 2, 2, 2-d5)-ethoxy-
pyridinyl)hydroxy-ethyl]—amide,'
: (1 S, 2S)(4-Fluoro-phenyl)-cyclopropanecarboxy/ic acid [(R)-1 -(6-(2, 2, 2-d3)-ethoxy-
pyridinyl)hydroxy-ethyl]—amide,'
36: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(R)(6-(1, 1 -d2)-ethoxy-pyridin-3—yl)—2-
hydroxy-ethy/]—amide,'
37: (1 S, 2S)(4-Fluoro-phenyl)-cyclopropanecarboxy/ic acid [(R)(6-(1, 1 -d2)-ethoxy-pyridin-
3—yl)hydroxy-ethy/]—amide,'
38: (1 S, Phenyl—cyclopropanecarboxy/ic acid [(R)(6-(1, 1, 2, 2, ethoxy-pyridin
hydroxy-ethy/J—amide,‘
39: (1 S, 2S)(3-F/uoro-phenyl)—cyclopropanecarboxy/ic acid [(R)(6-(2, 2, 2-d3)-ethoxy-
pyridinyl)hydroxy-ethyl]—amide,'
40: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(R)(6-cyc/obutoxy-pyridin-3—yl)—2-
hydroxy-ethy/]—amide,'
41 : (1 S, 2S)(3-F/uoro-phenyl)—cyclopropanecarboxy/ic acid -(6-cyc/obutoxy-pyridin-3—
y/)hydroxy-ethy/J—amide,‘
42: (1 S, 2S)(4-F/uoro-phenyl)-cyc/opropanecarboxy/ic acid -(6-cyc/obutoxy-pyridin-3—
y/)hydroxy-ethy/J—amide,‘
43: (1 S, 2S)Phenyl—cyclopropanecarboxylic acid ((R)hydroxy{6-[(R)-(tetrahydro-furan-
3—yl)oxy]-pyridin-3—yl}-ethy/)-amide,'
44: (1 S, [(1 R)hydroxy[6-[(38)-tetrahydrofuran-3—y/Joxypyridyljethyl]—2-phenyl—
cyc/opropanecarboxamide,‘
45: (1 S, 28)—2-((Z)Methy/ene—pem‘a-2, 4-dienyl)-cyclopropanecarboxy/ic acid {(R)
hydroxy[6-(tetrahydro-pyranyloxy)—pyridiny/]-ethy/}-amide,'
46: (1 S, 2S)Phenyl—cyc/opropanecarboxylic acid [(R)(6-ethoxy-pyridin-3—y/)methoxy-
ethy/J-amide;
47: (1 S, 2S)-N-[(1R)—2-methoxy[6-[(3R)-tetrahydrofuran-3—yl]oxy-3—pyridyl]ethy/J—2-phenyl-
cyc/opropanecarboxamide,‘
48: (1 S, 2S)-N-[(1R)—2-methoxy[6-[(3S)-tetrahydrofuran-3—yl]oxy-3—pyridy/]ethy/J—2-phenyl—
cyc/opropanecarboxamide,‘
[Annotation] sak
49: (1 S, 2S)-2—Phenyl—cyclopropanecarboxylic acid {(R)-2—methoxy[6-(tetrahydro-pyran
yloxy)-pyridinyl]-ethyl}-amide;
50: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid {(8)[6-(oxetanyloxy)-pyridinyl]—
ethyl}-amide;
51 : (1 S, 2S)Phenyl-cyclopropanecarboxy/ic acid [(S)(6-ethanesulfonyl
-pyridinyl)-ethyl]—amide;
52: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(R)(5-ethoxy-pyridin-
2-hydroxy-ethy/]—amide;
and pharmaceutically acceptable salts of any of these compounds.
E33. A nd according to any of embodiments 1-32, for use as a medicament.
E34. A compound according to any of embodiments 1-32, for use in therapy.
E35. A compound ing to any of embodiments 1-32, for use in the treatment of a dis-
ease or disorder selected from Psychosis; Schizophrenia; ive disorders; cognitive im-
pairment associated with schizophrenia; Attention Deficit Hyperactivity Disorder ; au-
tism spectrum disorders, Alzheimer’s disease (AD); mild cognitive impairment (MCI); age as-
sociated memory ment (AAMI); senile ia; AIDS dementia; Pick's disease; de-
mentia associated with Lewy bodies; dementia associated with Down's syndrome; Hunting-
ton's Disease; Parkinson’s disease (PD); obsessive-compulsive disorder (OCD); traumatic
brain injury; epilepsy; post-traumatic stress; Wernicke-Korsakoff syndrome (WKS); post-
traumatic amnesia; ive deficits associated with depression; diabetes, weight control,
matory disorders, reduced angiogenesis; ophic lateral sclerosis and pain.
E36. The compound according to embodiment 35, wherein said a disease or disorder is
selected from schizophrenia; AD; ADHD; autism spectrum disorders; PD; amyotrophic lateral
sclerosis; Huntington's disease; dementia associated with Lewy bodies and pain.
E37. The compound according to embodiment 36, wherein said e or disorder is se-
lected from schizophrenia; AD; ADHD and autism spectrum disorders.
E38. The compound according to embodiment 37, wherein said disease or disorder is se-
lected from negative and/or ive symptoms of schizophrenia.
[Annotation] sak
E39. The compound ing to any of embodiments 1-32, for use concomitantly or se-
quentially with a therapeutically ive amount of a compound selected from the list consisting
of acetylcholinesterase inhibitors; glutamate receptor antagonists; dopamine transport
inhibitors; noradrenalin transport inhibitors; D2 antagonists; D2 partial agonists; PDE10 an-
tagonists; 5-HT2A antagonists; 5-HT6 antagonists; KCNQ antagonists; lithium; sodium chan-
nel blockers and GABA signaling enhancers in the treatment of a disease or disorder accord-
ing to any of embodiments 35-38.
E40. A pharmaceutical composition comprising a compound according to any of embodi-
ments 1-32, and one or more pharmaceutically acceptable carrier or excipient.
E41. The composition according to embodiment 40, which composition additionally com-
prises a second compound selected from the list consisting of acetylcholinesterase inhibitors;
glutamate receptor antagonists; dopamine transport inhibitors; noradrenalin transport inhibi-
tors; D2 antagonists; D2 l ts; PDE10 antagonists; 5-HT2A antagonists; 5-HT6
antagonists; KCNQ antagonists; m; sodium channel blockers and GABA signaling en-
hancers.
E42. The composition according to embodiment 41, wherein said second compound is an
acetylcholinesterase inhibitor.
E43. A kit comprising a nd according to any of embodiments 1-32, together with a
second compound selected from the list consisting of cholinesterase inhibitors; gluta-
mate receptor antagonists; dopamine transport inhibitors; noradrenalin transport inhibitors;
D2 antagonists; D2 partial agonists; PDE10 antagonists; 5-HT2A antagonists; 5-HT6 antago-
nists; KCNQ nists; m; sodium l blockers and GABA signaling enhancers.
E44. The kit according to embodiment 43, wherein said second compound is an acetylcho-
linesterase inhibitor.
E45. A method for the treatment of a disease or disorder selected from Psychosis; Schizo-
phrenia; cognitive disorders; cognitive impairment ated with schizophrenia; Attention
Deficit Hyperactivity Disorder (ADHD); autism spectrum disorders, Alzheimer’s disease (AD);
mild ive impairment (MCI); age associated memory impairment (AAMI); senile demen-
tia; AIDS dementia; Pick's disease; ia associated with Lewy bodies; dementia -
ated with Down's syndrome; gton's Disease; Parkinson’s disease (PD); obsessive-
[Annotation] sak
compulsive disorder (OCD); traumatic brain injury; epilepsy; post-traumatic stress; Wernicke-
Korsakoff syndrome (WKS); post-traumatic a; cognitive deficits associated with de-
pression; diabetes, weight control, matory disorders, reduced angiogenesis; amyotro-
phic lateral sclerosis and pain, which method comprises the administration of a therapeuti-
cally effective amount of a compound according to any of embodiments 1-32 to a patient in
need thereof.
E46. The method according to embodiment 45, wherein said disease or disorder is selected
from schizophrenia; AD; ADHD; autism spectrum disorders; PD; amyotrophic lateral sclerosis;
Huntington's e; dementia associated with Lewy bodies and pain.
E47. The method according to embodiment 46, wherein said disease or disorder is ed
from schizophrenia; AD; ADHD and autism spectrum disorders.
E48. The method according to embodiment 47, wherein said treatment comprises the treat-
ment of negative and/or cognitive symptoms of schizophrenia.
E49. The method according to any of embodiments 45-48, wherein said treatment further
comprises the administration of a therapeutically effective amount of a second compound se-
lected from the list consisting of acetylcholinesterase inhibitors; glutamate receptor antago-
nists; dopamine transport inhibitors; noradrenalin transport inhibitors; D2 nists; D2
partial agonists; PDE10 nists; 5-HT2A antagonists; 5-HT6 antagonists; KCNQ -
nists; lithium; sodium channel blockers and GABA signaling enhancers.
E50. The method according to embodiment 49, wherein said second compound is an ace-
tylcholinesterase inhibitor.
E51. Use of a compound ing to any of embodiments 1-32, for the manufacture of a
medicament for the treatment of a disease or er selected from sis; Schizophre-
nia; cognitive disorders; cognitive impairment associated with schizophrenia; Attention Deficit
Hyperactivity Disorder (ADHD); autism spectrum disorders, Alzheimer’s disease (AD); mild
cognitive impairment (MCI); age associated memory ment (AAMI); senile dementia;
AIDS dementia; Pick's disease; dementia ated with Lewy bodies; dementia associated
with Down's syndrome; Huntington's Disease; Parkinson’s disease (PD); obsessive-
compulsive disorder (OCD); traumatic brain injury; epilepsy; post-traumatic ; ke-
Korsakoff syndrome (WKS); post-traumatic amnesia; cognitive ts associated with de-
[Annotation] sak
pression; diabetes, weight control, inflammatory disorders, reduced angiogenesis; amyotro-
phic lateral sclerosis and pain.
E52. The use according to embodiment 51, wherein said disease or disorder is selected
from schizophrenia; AD; ADHD; autism um disorders; PD; amyotrophic lateral sis;
Huntington's disease; dementia associated with Lewy bodies and pain.
E53. The use according to embodiment 52, n said e or disorder is ed
from schizophrenia; AD; ADHD and autism spectrum disorders.
E54. The use according to embodiment 53, wherein said disease is the positive, negative
and/or ive symptoms of schizophrenia.
E55. The use according to any of embodiments 51-54, wherein said manufacture r
comprises the use of a second compound ed from the list consisting of acetylcholi-
nesterase inhibitors; glutamate receptor antagonists; dopamine transport inhibitors;
noradrenalin ort inhibitors; D2 antagonists; D2 partial agonists; PDE10 antagonists; 5-
HT2A antagonists; 5-HT6 antagonists; KCNQ antagonists; lithium; sodium channel blockers
and GABA signaling enhancers.
E56. The use ing to embodiment 55, wherein said second compound is an acetyl-
cholinesterase inhibitor.
The compounds of the invention may exist in unsolvated as well as in solvated forms
in which the solvent molecules are selected from pharmaceutically acceptable solvents such
as water, l and the like. In general, such solvated forms are considered equivalent to
the unsolvated forms for the purposes of this invention.
Included in this invention are also isotopically labeled compounds, which are identical
to those claimed in formula [I], wherein one or more atoms are represented by an atom of the
same element having an atomic mass or mass number different from the atomic mass or
mass number usually found in nature (e.g., 2H, 3H, 11C, 130, 15N, 18F and the like). Particular
mention is made of 2H substituted compounds i.e. compounds wherein one or more H atoms
are represented by deuterium. In one ment of the invention one or more of the hydro-
gen atoms of the compound of a [I] are represented by deuterium. It is ized that
elements are present in natural isotopic abundances in most synthetic compounds, and result
in inherent incorporation of deuterium. However, the natural isotopic abundance of hydrogen
[Annotation] sak
isotopes such as deuterium is immaterial (about 0.015%) ve to the degree of stable iso-
topic substitution of compounds indicated herein. Thus, as used herein, designation of an
atom as deuterium at a position indicates that the abundance of deuterium is significantly
greater than the natural abundance of deuterium. Any atom not ated as a particular
isotope is intended to represent any stable isotope of that atom, as will be apparent to the or-
dinarily skilled artisan.
In one embodiment, designation of a position as “D” in a compound has a minimum
deuterium incorporation of greater than about 60% at that position such as greater than about
70% at that on such as greater than about 80% at that position such as greater than
about 85% at that position. In a further embodiment, designation of a on as “D” in a
compound has a minimum deuterium incorporation of greater than about 90% at that position
such as greater than about 95% at that on such as greater than about 97% at that posi-
tion such as greater than about 99% at that position.
The compounds of the t invention have three asymmetric centers with fixed
stereochemistry indicated by the arrows below.
The compounds of the present invention can be manufactured from two chiral inter-
mediates with one and two asymmetric centers, respectively, as rated by the examples
below.
In this context is understood that when specifying the enantiomeric form of the inter-
e, then the intermediate is in enantiomeric excess, e.g. essentially in a pure, mono-
enantiomeric form. Accordingly, the resulting compounds of the invention are having a di-
astereomeric excess of at least 80%. One embodiment of the invention relates to a com-
pound of the invention having a diastereomeric excess of at least 80% such as at least 85%,
such as at least 90%, ably at least 95% or at least 97% with reference to the three as-
symetric centers ted above.
Dependent on the individually substituents R1-R14, the nds of the t in-
vention may furthermore have one or more additional asymmetric centers. It is intended that
any optical isomers (i.e. enantiomers or diastereomers), in the form of separated, pure or par-
tially purified optical isomers and any es thereof including racemic mixtures, Le. a mix-
ture of stereoisomers, which have emerged because of asymmetric centers in any of sub-
stituents R1-R14, are included within the scope of the invention.
[Annotation] sak
Racemic forms can be resolved into the optical antipodes by known methods, for ex-
ample by separation of reomeric salts f with an optically active acid, and liberat-
ing the optically active amine compound by ent with a base. Another method for -
ing racemates into the optical antipodes is based upon chromatography of an optically active
matrix. The compounds of the present invention may also be resolved by the formation of di-
astereomeric derivatives. Additional methods for the resolution of optical isomers, known to
those skilled in the art, may be used. Such methods include those discussed by J. Jaques, A.
Collet and S. Wilen in “Enantiomers, Racemates, and Resolutions”, John Wiley and Sons,
New York . Optically active compounds can also be prepared from optically active
starting materials.
Furthermore, when a double bond or a fully or partially saturated ring system is pre-
sent in the molecule geometric isomers may be formed. It is intended that any geometric iso-
mers, as separated, pure or lly ed geometric isomers or mixtures thereof are in-
cluded within the scope of the invention. Likewise, molecules having a bond with restricted
rotation may form geometric isomers. These are also intended to be included within the scope
of the present invention.
Furthermore, some of the compounds of the present invention may exist in different
tautomeric forms and it is intended that any tautomeric forms that the compounds are able to
form are included within the scope of the present invention.
The compounds of the present ion may be administered alone as a pure com-
pound or in combination with ceutically acceptable rs or excipients, in either sin-
gle or multiple doses. The pharmaceutical compositions according to the invention may be
formulated with pharmaceutically acceptable carriers or diluents as well as any other known
adjuvants and ents in accordance with conventional techniques such as those disclosed
in Remington: The Science and Practice of Pharmacy, 19 Edition, Gennaro, Ed., Mack Pub-
lishing 00., Easton, PA, 1995.
The pharmaceutical compositions may be specifically formulated for administration by
any suitable route such as the oral, rectal, nasal, pulmonary, l (including buccal and
sublingual), transdermal, intracisternal, intraperitoneal, vaginal and eral (including sub-
cutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being
preferred. It will be appreciated that the preferred route will depend on the general condition
and age of the subject to be d, the nature of the condition to be treated and the active
ingredient chosen.
Pharmaceutical compositions for oral administration include solid dosage forms such
as capsules, tablets, dragees, pills, lozenges, powders and granules. Where riate, they
can be prepared with coatings.
[Annotation] sak
Liquid dosage forms for oral administration include solutions, emulsions, suspensions,
syrups and elixirs.
Pharmaceutical itions for parenteral administration include sterile aqueous and
nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile
powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
Other suitable administration forms include suppositories, sprays, ointments, cremes, gels,
inhalants, dermal patches, implants, etc.
In one ment, the compound of the present invention is administered in an
amount from about 0.001 mg/kg body weight to about 100 mg/kg body weight per day. In par-
ticular, daily dosages may be in the range of 0.01 mg/kg body weight to about 50 mg/kg body
weight per day. The exact dosages will depend upon the frequency and mode of administra-
tion, the sex, the age the weight, and the general condition of the subject to be treated, the
nature and the severity of the condition to be d, any concomitant es to be treated,
the desired effect of the treatment and other factors known to those d in the art.
A typical oral dosage for adults will be in the range of 0.1-1000 mg/day of a compound
of the present invention, such as 1-500 mg/day, such as 1-100 mg/day or 1-50 mg/day.
Conveniently, the compounds of the ion are administered in a unit dosage form contain-
ing said nds in an amount of about 0.1 to 500 mg, such as 10 mg, 50 mg 100 mg, 150
mg, 200 mg or 250 mg of a compound of the present invention.
For parenteral administration, solutions of the compound of the invention in sterile
s solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may
be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid
diluent first rendered isotonic with sufficient saline or e. The aqueous solutions are par-
ticularly suitable for intravenous, intramuscular, aneous and eritoneal administra-
tion. The sterile aqueous media employed are all readily available by standard techniques
known to those skilled in the art.
Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous
solution and s organic solvents. Examples of solid carriers are lactose, terra alba, su-
crose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and
lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil,
phospho lipids, fatty acids, fatty acid amines, yethylene and water. The pharmaceutical
compositions formed by combining the compound of the invention and the pharmaceutical
acceptable carriers are then readily stered in a y of dosage forms suitable for the
disclosed routes of administration.
Formulations of the t invention suitable for oral administration may be pre-
sented as discrete units such as capsules or tablets, each containing a predetermined
[Annotation] sak
amount of the active ingredient, and which may e a suitable excipient. Furthermore, the
orally available formulations may be in the form of a powder or granules, a solution or sus-
pension in an s or ueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
If a solid carrier is used for oral administration, the preparation may be tablet, e.g.
placed in a hard gelatine capsule in powder or pellet form or in the form of a troche or loz-
enge. The amount of solid carrier may vary but will usually be from about 25 mg to about 1 g.
If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gela-
tine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension
or solution.
Tablets may be prepared by mixing the active ingredient with ordinary adjuvants
and/or diluents followed by the compression of the mixture in a conventional tabletting ma-
chine. Examples of nts or diluents comprise: Corn starch, potato starch, talcum, mag-
nesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usu-
ally used for such purposes such as colourings, flavourings, preservatives etc. may be used
provided that they are compatible with the active ingredients.
All references, ing publications, patent applications, and patents, cited herein
are hereby incorporated by reference in their entirety and to the same extent as if each refer-
ence were individually and specifically indicated to be incorporated by reference and were set
forth in its entirety herein (to the maximum extent permitted by law), regardless of any sepa-
rately provided incorporation of particular nts made elsewhere herein.
The use of the terms “a” and “an” and “the” and similar referents in the context of de-
scribing the invention are to be construed to cover both the ar and the , unless
otherwise indicated herein or clearly contradicted by context. For example, the phrase "the
compound" is to be understood as referring to s "compounds" of the invention or par-
ticular described aspect, unless othenNise indicated.
The description herein of any aspect or aspect of the invention using terms such as
“comprising”, “having,” “including,” or “containing” with reference to an element or elements is
intended to provide support for a similar aspect or aspect of the ion that “consists of”,
“consists essentially of”, or “substantially comprises” that particular element or elements,
unless ise stated or clearly contradicted by context (e.g., a composition described
herein as comprising a particular element should be understood as also describing a compo-
sition consisting of that element, unless otherwise stated or clearly contradicted by context).
It should be understood that the various aspects, embodiments, implementations and
es of the invention ned herein may be claimed tely, or in any combination.
[Annotation] sak
The compounds of formula I may be prepared by methods described below, together
with synthetic methods known in the art of organic chemistry, or modifications that are familiar
to those of ordinary skill in the art. The starting materials used herein are available commer-
cially or may be prepared by routine methods known in the art, such as those method de-
d in rd reference books such as “Compendium of Organic Synthetic Methods,
Vol. l-Xll” shed with Wiley-lnterscience). Preferred methods include, but are not limited
to, those described below.
The schemes are representative of methods useful in synthesizing the compounds of
the present invention. They are not to constrain the scope of the invention in any way.
Methods of Preparation of the Compounds of the Invention.
The nds of the invention with formula I can be ed from intermediate Ill and II as
described in Scheme 1.
Scheme 1
If X is a hydroxyl, the carboxylic acid II and the amine Hi can be condensed to form the
amide I using standard peptide coupling chemistry, e.g. as described in the textbook Syn-
thetic Peptides A user’s Guide (Edited by Gregory A. Grant, W H. Freeman and company
(1992) ISBN 07009-1) or as described in the ok Houben-Wey/ Volume E22a
Synthesis of es (George Thiemes Ver/ag Stuttgart (2003) 4th ed.). One example of this
amide formation is the use of the coupling t HATU (O-(benzotriazolyl)-N,N,N’,N’-
ethyluronium hexafluorophosphate). Typically, one eq. of II is reacted with one eq. of
HATU in the presence of two eq. of a tertiary amine e.g. triethylamine in a suitable t
e.g. DMF. After a short period of time (e.g. five minutes) this mixture is reacted with one eq. of
III to form |. Another example of this amide formation uses 1-hydroxybenzotriazole together
with the water soluble carbodiimide EDC (CAS 259528) and triethyl amine in a suitable
solvent e.g. THF. These reactions are usually performed at room ature or between 0
0C and 50 0C.
[Annotation] sak
If X is a chloride (e.g. prepared from the carboxylic acid ll, X = OH, using thionyl chloride) lll
can be reacted with II to form | in the presence of a tertiary amine in a suitable solvent. Alter-
natively, the carboxylic acid chloride (ll, X = Cl) can be d with N-hydroxy succinimide to
produce the HOSU ester which can be isolated and then reacted with I” to e |.
Methods of Preparation of the Intermediates of the Invention.
The Intermediates of the invention with formula II are either commercially available or
can be prepared as described in Scheme 2.
R4 R4
R3 R5 R3 R5
R2 0 R2 0
R1 R1 K
racemic-trans-ll ethylester
R3 R5 SFC separation
R2 OH
racemic trans || "
Scheme 2. Preparation of the (1S, 2S) enantiomer of a II.
Ethyldiazoacetate can be d with the styrene in Scheme II to produce the race-
ans ll ethyl ester. This ester can then be hydrolyzed to racemic trans II which can then
be separated into the two enantiomers using SFC. Alternatively, racemic trans II can be re-
solved into the two enantiomers by known methods as described in the textbook “Enanti-
omers, Racemates and Resolutions” (J. Jaques, et al., John Wiley and sons, New York
(1981)).
r preparation of the compounds with formula II is described in Scheme 3. This
method has been described in detail in W02012/O37258
[Annotation] sak
R4 R4
R3 R5 OEt R3 R5
EtO\ I OtBU —S—
NaH LiOH
+ PW I
H —»
H / OtBu —> —’
R2 0 O Toluene R2 NaOtBu
R1 0 R1 0 DMSO
R3 R5
R2 OH Separation
racemic trans ll "
Scheme 3. Preparation of the (1S, ZS) enantiomer of a II.
The benzaldehyde shown in Scheme 3 can be reacted with the anion of (Diethoxy-
phosphoryl)—acetic acid tert-butyl ester to produce the unsaturated ester shown. Cylopropana-
tion followed by hydrolysis then produces Racemic trans II, which can be ted as de-
scribed above.
The lntermediates of the invention with formula III are either commercially available or
can be prepared as described in Scheme 4 in which R5 is CHZOH.
Br A“
/ is9
0 H
OSITBS
' 0 R10
S\NH + O
_> g —>
/ /
2 OSiTBS tBU \N BuLi
OSiTBS OSITBS OH
i '/
i
s A s A A
t /Bu \N 7¢ + /
As Bu \N 7¢ 7?
I A I As H2N As
H H A _. I
/ /A 9 / 9 9
R11 R11 R11
R10 R10 R10
Scheme 4. ation of the chiral amines of formula III, with R5 = CHZOH. The method is
described in: Barrow, J. C. et al. Tetrahedron Letters (2001) 2051.
[Annotation] sak
(R)—(+)methylpropanesulfinamide can be reacted with (tertbutyldimethylsilyloxy
ldehyde as bed in the literature (Barrow, J. C. et al. Tetrahe-
dron Letters (2001) 2051) to e the sulfinimine shown in Scheme 4. 1,2- addition of an
organometallic (e.g. a Grignard reagent or an aryllithiumreagent (shown in Scheme 4) re-
agent to this sulfinyl imines then gives the two diastereomeric protected amino alcohols
shown in scheme 4. These isomers can be separated e.g. by silica gel chromatography and
the protecting groups are then removed under acidic conditions.
Another method using enantiopure tert-butanesulfinamide is shown in Scheme 5
(Robak, M., Herbage, M., Ellman, Chem. Rev. 2010, 110, 3600-3740 and references cited
herein). For simplicity, the method is only rated for R5 = CH3, but the method is not lim-
ited to R5 = CH3.
I I8 ion
X8\ +
_, —>
NHz 9
0 o
t t
/l A
\N 7\\ + A
/l A
B” As B” \N 7C 7C
As HZN As
H —» I H I I
/l 9 /l /l 9 9
R11 R11 R11
R10 R10 R10
Minor isomer Major isomer
Scheme 5. Preparation of the chiral amines of formula III, with R5 = CH3. The method is de-
scribed in: Robak, M., Herbage, M., Ellman, Chem. Rev. 2010, 110, 3600-3740 and refer-
ences cited herein.
(R)—(+)methylpropanesulfinamide can be reacted with a suitable ketone and titanium
(lV)ethoxide in a suitable solvent e.g. THF under heating conditions to produce the
sulfinyl imine shown in scheme 5. This imine can be d, with some selectivity using a
reducing agent (e.g. L-selectride) in a suitable solvent (e.g. THF) at a suitable ature
(e.g. -70 0C) to produce the major and the minor isomer shown in Scheme 5. The major iso-
mer can be isolated by e.g. silica gel chromatography and the chiral auxiliary can then be re-
moved with acid (e.g. HCI in water to produce lll).
EXAMPLES
[Annotation] sak
The ion will be illustrated by the following non-limiting examples.
Abbreviations
AcOH = acetic acid. OLD = specific optical rotation. Aq = Aqueous. BBr3 = boron tribromide
(used as DCM solution; Aldrich 17,893-4). Boc20 = Boc anhydride / di-t—butyl dicarbonate
(e.g. Aldrich 19,913-3). Brine = saturated aqueous on of sodium chloride. CDCI3 deuter-
ated chloroform (e.g. Aldrich 225789). Celite = filter-aid. CH3| = methyl iodide / iodomethane
(e.g. Aldrich 28,956-6). Cs2C03 = cesium carbonate (Aldrich 441902). DCM = dichloro-
e. DMF = yl formamide. DMSO = dimethyl sulfoxide. ds-DMSO = deutorated
yl ide (e.g. Aldrich 296147). ELSD = evaporative light scattering detection. Et3N =
triethyl amine. EtOAc = ethyl acetate. 99% EtOH = te ethanol. EtZO = diethyl ether. h =
hours. HATU = O-(7-Azabenzotriazoly|)-N,N,N’,N’-tetramethyluronium hexaflouruphos-
phate. HBTU = 2-(1H-Benzotriazolyl)—1,1,3,3-tetramethyluronium hexaflourophosphate. i=
iso. K2C03 = ium carbonate (e.g. Aldrich 20,961-9). LDA = lithium ropylamide
(used as a THF/heptane/ethylbenzene solution; Fluka 62491 ). LC/MS = high-performance
liquid chromatography / mass ometer. LAH = lithium aluminium hydride (used as a 1M
THF solution; Aldrich 21,277-6). MeOH = methanol. min = minutes. NaCNBH3 = sodium
cyanoborohydride (Aldrich 15,615-9). NaH = sodium hydride (used as a 60% dispersion;
Aldrich 45,291-2). NaOH = gueous solution of sodium hydroxide. Pd/C = palladium-on-
charcoal (e.g. Aldrich 20,569-9). PTSA = para-toluene sulfonic acid hydrate (e.g. Aldrich
—5). rt = room temperature. RT = retention time. sat. NaHCOs = saturated s so-
lution of sodium hydrogen carbonate. sat. NH4C| = saturated aqueous solution of ammonium
chloride. SFC = supercritical flash chromatography. TFA = trifluoroacetic acid. THF = tetrahy-
drofuran (dried over 4A molecular sieves). TLC = thin layer chromatography.
Chemical names were obtained using the software MDL RAW 2.5 from MDL informa-
tion systems
Spectroscopic methods.
Method A:
LC-MS were run on a Sciex AP|150EX equipped with APPl-source operating in positive ion
mode. The HPLC consisted of Shimadzu LC10-ADvp LC pumps, SPD-M20A PDA detector
(operating at 254 nm) and SCL-10A system controller. Autosampler was Gilson 215, Column
oven was a Jones Chromatography 7990R and ELS detector was a Sedere Sedex 85.
[Annotation] sak
LC-conditions: The column was a Waters Symmetry C-18, 4.6x30 mm, 3.5 pm operating at
60°C with 3.0 mL/min of a binary gradient consisting of water + 0.05% TFA (A) and methanol
+ 0.05% TFA (B).
Gradient:
0.01 min 17% B
0.27 min 28% B
0.53 min 39% B
0.80 min 50% B
1.07 min 59% B
1.34 min 68% B
1.60 min 78% B
1.87 min 86% B
2.14 min 93% B
2.38 min 100% B
2.40 min 17% B
2.80 min 17% B
Total run time: 2.8 min.
The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
Method B:
LC-MS were run on Waters Acquity UPLC-MS consisting of Waters Acquity including column
mamager, binary solvent manager, sample organizer, PDA or (operating at 254 nM),
ELS detector, and SQD-MS ed with APPl-source operating in positive ion mode.
LC-conditions: The column was Acquity UPLC BEH C18 1.7um ; 2.1x50mm ing at 60°C with
1.2 ml/min of a binary gradient consisting of water + 0.05 % trifluoroacetic acid (A) and acetonitrile +
% water + 0.035 % trifluoroacetic B)
Gradient:
0.00 min 10% B
1.00 min 100% B
1.01 min 10% B
1.15 min 10% B
Total run time: 1.2 min.
The retention times (tR) are expressed in minutes based on UV-trace at 254 nm.
[Annotation] sak
Method C:
Preparative supercritical fluid chromatography (SFC) was performed on a Berger ram ll
operating at 50 mL/min at 35°C and 100 bar backpressure using stacked injections. The col-
umn was a pakAD 5 u, 250x21 mm. The eluent was C02 (70%) and ethanol (30%).
Method D:
Preparative supercritical fluid chromatography (SFC) was performed on a Thar SFC-80 oper-
ating at 60 g/min at 35°C and 140 bar backpressure using stacked injections. The column
was a ChiralPakAD-H (250x30 mm). The eluent was C02 (88%) and Ethanol (12%).
Method E:
Preparative supercritical fluid chromatography (SFC) was performed on a Thar SFC-200 op-
erating at 100 g/min at 35°C and 140 bar backpressure using stacked injections. The column
was a ChiralPakAD-H (250x30 mm). The eluent was C02 (90%) and Ethanol (10%).
Method F:
omeric excess (ee) was determined on an Aurora Fusion A5 SFC system operating at
3 ml/min at 40 °C and 100 bar backpressure. The column was a Chiralpak AD (150x4.6 mm).
The eluent was C02 (70%) and ethanol + 0.1% diethyl amine (30%).
1H NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX-500 ment at
T=303.3 K or at 600 MHz on a Bruker Avance AV-lll-600 instrument. Chemical shift values
are expressed in ppm-values relative to tetramethylsilane unless noted otherwise. The follow-
ing abbreviations or their combinations are used for multiplicity of NMR signals: s = singlet, d
= t, m = let and br = broad.
Preparation of intermediates
Pre aration of bromo s.
IM1 : 5-Bromo-2—isopropoxy—pyridine
BraI k\
60% NaH in 0“ (15:1, Sodium hydride:Minera| Oil, 5.20 g) was added in two ns to iso-
propyl alcohol (150 mL) at room temperature under N2. The mixture was stirred at 60°C for 30
min. 5-bromochloropyridine (10.00 g, 51.96 mmol) was added in two portions and the mix-
ture was stirred at reflux 4h and then at 80°C overnight. The solution was concentrated in
[Annotation] sak
vacuo. Water (50 mL) and EtOAc (50 mL) was added and the layers were separated. The
aqueous layer was extracted with EtOAc (50 mL). The combined organic layers were washed
with brine, dried over MgSO4, filtered and the solvent was removed in vacuo. The crude prod-
uct was subjected to flash chromatography a, 0-50% EtOAc in heptanes) to give the title
compound as a clear oil (8.74 g, 78%). 1H NMR (600 MHz, DMSO) 6 8.17 (s, 1H), 7.61 (dd,
1H), 6.59 (d, 1H), 5.23 (m, 1H), 1.33 (s, 6H).
IM2: 5-Bromo(2, 2, 2-trifluoro-ethoxy)-pyridine
Prepared analogously to IM1 to give the title compound as a ess liquid (2.78 g, 54%)
iently pure for the next step.
IM3: 5-Bromopropoxy—pyridine
Potassium tert—butoxide (1.85 g, 16.5 mmol) was added to a mixture of 5-bromo
chloropyridine (2.89 g, 15.0 mmol) and 1-propanol (1.230 mL, 16.5 mmol) in THF (15 mL).
The reaction mixture was heated at 120°C for 30 minutes in a microwave reactor. The mixture
was poured into a mixture of water (50 mL) and EtOAc (100 mL). The organic layer was
washed with brine, dried over MgSO4 and evaporated to s. Flash chromatography (sil-
ica, 0-20% EtOAc in heptanes) gave the title compound as a yellow oil (3.13 g, 97%) suffi-
ciently pure for the next step.
IM4: 5-Bromo(2, 2, 2-d3)-ethoxy-pyridine
[Annotation] sak
Prepared analogously to IM3 using commercially available 2,2,2-d3-ethanol -Aldrich,
catalog no 329347) to give the title compound as a colorless oil (2.53 g, 82%) sufficiently pure
for the next step.
IM5: 5-Bromo-2—(1
, 1, 2, 2, 2-d5)-ethoxy-pyridine
Prepared ously to IM3 using commercially available 1,1,2,2,2-d5-ethanol -
Aldrich, g no 489336) to give the title compound as a colorless oil (1.16 g, 87%) suffi-
ciently pure for the next step.
IM6: 5-Bromo-2—(1 1 -d2)-ethoxy-pyridine
Prepared analogously to IM3 using commercially available 1,1-d2-ethanol (Sigma-Aldrich,
catalog no ) to give the title compound as a colorless oil (2.61 g, 85%) sufficiently pure
for the next step.
IM7: 5-Bromo-2—(2—methoxy—ethoxy)-pyridine
2-Methoxyethanol (5.12 mL, 65.0 mmol) was dissolved in 1,4-dioxane (125 mL). Potassium
tert—butoxide (7.00 g, 62.4 mmol) was added under N2. The mixture was stirred for 10 min-
utes. 5-Bromochloropyridine (10.0 g, 52.0 mmol) was added and the resulting mixture was
refluxed for 2 hours. The mixture was poured into brine and extracted with EtOAc. The or-
ganic layer was washed with brine, dried over MgSO4 and evaporated to s. Purification
by flash chromatography (silica, heptanes/EtOAc 4:1) gave the title compound as a colorless
oil (8.74 g, 73%) sufficiently pure for the next step.
IM8: 5-Bromomethoxymethyl-pyridine
[Annotation] sak
\' 0\
To a solution of 5-bromopyridinecarbaldehyde (5.00 g, 26.9 mmol) dissolved in a e
of ethanol (75 mL) and THF (25 mL) was added sodium borohydride (0.407 g, 10.8 mmol) in
small portions. After 45 minutes 0.5 mL water was added and the mixture and evaporated to
dryness. The oily residue was subjected to flash chromatography (silica, EtOAc/EtOH/Et3N
90:5:5) to give (5-bromo-pyridinyl)—methanol (4.81 g, 86%) as pale-yellow oil.
A solution of this (5-bromo-pyridinyl)—methanol (4.80 g, 23.0 mmol) in DMF (25 mL) was
added drop wise over 5 minutes to a slurry of sodium hydride (1.10 g, 27.6 mmol) in DMF (50
mL) at 0 °C under N2. The mixture was stirred for 15 s before the drop wise addition of
a solution of methyl iodide (1.57 mL, 25.3 mmol) in DMF (25 mL). The mixture was allowed to
reach room temperature and was then stirred overnight. The mixture was poured into brine
and extracted with EtOAc. The combined organic layers were thoroughly washed with brine,
dried over MgSO4 and ated to dryness to give the title compound as a yellow oil (4.77
g, 98%) sufficiently pure for the next step.
IM9: 5-Bromocyc/obutoxy—pyridine
Prepared analogously to IM3 using commercially available cyclobutanol to give the title nd
as a clear oil (2.72 g, 80%) sufficiently pure for the next step.
IM1 0: 5-Bromo[(R)-(tetrahydro-furanyl)oxy]—pyridine
To a solution of 5-bromochloropyridine (10 g, 52.1 mmol) in 100 mL of DMF was added
commercially ble (R)—(-)—3-hydroxytetrahydrofuran (6.87 g, 78.1 mmol) and Cs2C03
(33.85 g, 0.104 mol), the resulting mixture was heated 90 °C for 36 hours. The solvent was
concentrated and the residue was extracted with EtOAc ), washed with water (200ml).
The organic layer was dried over NaZSO4, concentrated and purified by chromatography on
silica gel (eluting with Petrol ether: EtOAc = 100:1) to afford o[(R)-(tetrahydro-furan-
3-yl)oxy]—pyridine (5.9 g, yield: 47%) as a solid. 1HNMR (CDCI3 400MHz): 68.15 (d, J = 2.4
Hz, 1 H), 7.61-7.64 (m, 1 H), 6.64 (d, J: 8.8 Hz, 1 H), 5.47-5.50 (m, 1 H), 3.85-4.02 (m, 4 H),
2.07-2.28 (m, 2 H). [a1D20 = +18.5 (C=0.189, CHCI3).
[Annotation] sak
IM1 1 : 5-Bromo-2—[(S)-(tetrahydro-furanyl)ony-pyridine
Bra 0
\ u'
Prepared ously to IM10 using commercially available (S)-(+)hydroxytetrahydrofuran
to afford 5-Bromo[(S)-(tetrahydro-furany/)oxy]-pyridine
(9.62 g, yield: 51%) as a solid. 1HNMR (CDCI3400MHz): 68.16 (d, J = 2.4 Hz, 1 H), 7.62-
7.65 (m, 1 H), 6.64-6.66 (m, 1 H), 5.48-5.52 (m, 1 H), 3.99-4.03 (m, 2 H), 3.86-3.97 (m, 2 H),
2.20-2.29 (m, 1 H), 2.08-2.15(m, 1 H). [011020 = -20.7 (c=0.21, .
IM12: 5-Bromo(tetrahydro-pyranyloxy)-pyridine
Prepared analogously to IM3 using commercially available tetrahydropyranol to give the
title compound sufficiently pure for the next step.
IM1 3: 6-Bromo-[1, 3]dioxolo[4, 5-b]pyridine
Br Br
/ IN /
+ N
Br/\Br I
\ \
OH 0
OH 0J
To a suspension of o-pyridine-2,3-diol (10.0 g, 52.63 mmol, commercially available,
CAS 34206-49—0) in NMP (100 mL) was added K2C03 (21.97 g, 158 mmol) and dibromo
methane (10.97 g, 63.16 mmol). The reaction mixture was heated to 90 °C for 16 h. EtOAc
was added and the salts were filtered off. Water was added, the phases were separated and
the aq layer was extracted with more ethyl acetate. The combined organic layers was dried
over ous NaZSO4 and concentrated under vacuo to get the crude compound. The
crude compound was purified by silica gel chromatography (eluent 5 % ethyl acetate in petrol
ether). Yield of 6-Bromo-[1,3]dioxolo[4,5-b]pyridine 2.2 g (21%) pure by 1H NMR (400 MHz,
DMSO) 6 7.71 (d, 1H, J = 2 Hz), 7.55 (d, 1H, J = 2 Hz), 6.20 (s, 2H). Mp 69-71 C.
IM1 4: 7-Bromo-2, 3-dihydro-[1, 4]dioxino[2, 3-b]pyridine
[Annotation] sak
Br Br
/ IN
+ Br/W /
; IN
\ \
OH 3, 0
To a sion of 5-Bromo-pyridine-2,3-diol (10.0 g, 52.63 mmol, commercially available,
CAS 34206-49—0) in DMF (150 mL) was added K2C03 (21.78 g, 158 mmol) and 1,2-dibromo
ethane (11.87 g, 63.2 mmol). The reaction e was heated to 100 °C for 5 h. The reaction
mixture was cooled to rt and poured into ice cold water EtOAc was added and the phases
were separated and the aq layer was extracted with more ethyl acetate. The combined or-
ganic layers was dried over anhydrous NaZSO4 and concentrated under vacuo to get the
crude compound. The crude compound was purified by silica gel chromatography (eluent 10
% ethyl acetate in petrol ether). Yield of 6-Bromo-[1,3]dioxolo[4,5-b]pyridine 2.2 g (18 %) pure
by 1H NMR (400 MHz, DMSO) 6 7.85 (d, 1H, J = 2 Hz), 7.59 (d, 1H, J = 2 Hz), 4.41 (m, 2H),
4.27 (m, 2H).
Acetylation of pyridines.
IM15: 1-(6-Ch/oro-pyridin-3—y/)-ethanone
A round ed flask was charged with ochloropyridine (5.30 g, 27.6 mmol) in
THF under N2 and cooled at 0°C. A solution of 1 M iso-propylmagnesiumchloride - lithium
chloride complex in THF (40 mL) was added drop wise over 15 min. After 70 min N-methoxy-
N-methylacetamide (4.1 mL, 38 mmol) was added drop wise. After stirring for 5 min at 0 °C
the cooling bath was removed. The mixture was left stirring overnight and was then
quenched by the addition of 100 mL saturated aqueous NH4CI solution. The mixture was ex-
d with 3x100 mL EtOAc. The combined organic layers were washed with water followed
by brine and dried over MgSO4. Evaporation of the volatiles at 80 °C, 10 mbar for 1h gave the
title compound (3.596 g, 84) sufficiently pure for the next step.
IM16: 1 -(6-Iso-propoxy—pyridinyI)-ethanone
[Annotation] sak
A round-bottomed flask was d with 5-bromoiso-propoxypyridine (IM1) (5.00 g, 23.1
mmol) in THF (100) under N2 and cooled in an acetone/dry-ice bath to -66 °C (internal temperature
). A solution of2.5 M n-butyllithium in hexane (10.1 mL, 25.3 mmol) was added drop
wise over 10 minutes at keeping the internal temperature below -55 °C. The mixture was
stirred at -65 °C for 15 minutes. N-methoxy-N-methylacetamide (3.07 mL, 28.9 mmol) dis-
solved in THF (10 mL) was then added drop wise over 10 minutes while keeping the internal
temperature below -65 °C. After ng for 1 h the mixture was allowed to reach room tem-
perature. The mixture was poured into saturated aqueous NH4CI on and extracted with
EtOAc. The combined organic layers were washed with brine, dried over MgSO4 and evapo-
rated to dryness. Flash chromatography a, heptanes/EtOAc 4:1) gave the title compound
as a colorless oil (3.20 g, 77%) sufficiently pure for the next step.
IM17: 1 -(6-Methoxymethyl-pyridinyl)-ethanone
\ 0\
Prepared analogously to IM16 from IM8 to give the title compound as a colorless liquid (0.379
g, 17%) iently pure for the next step.
IM1 8: 1-[6-(2, 2, 2— Trifluoro-ethoxy)-pyridinyl]—ethanone
\ F
O/\F'<
Prepared analogously to IM16 from IM2 to give the title compound as a colorless liquid (1.234
g, 48%) sufficiently pure for the next step.
IM1 9: 1 -[6-(2-Methoxy—ethoxy)-pyridinyl]—ethanone
Prepared analogously to IM16 from IM7 to give the title compound as a colorless liquid (2.13
g, 57%) sufficiently pure for the next step.
IM20: 1-(2-Ethoxy-pyridinyl)-ethanone
[Annotation] sak
Prepared analogously to IM16 from cially available 4-bromoethoxy-pyridine,
Synchem OHG catalog no CT091 to give the title compound as a colorless liquid (1.20 g,
49%) sufficiently pure for the next step.
IM21 : 1-[1, 3]Dioxolo[4, ridiny/—ethanone
A round-bottomed flask was d with 6-Bromo-[1,3]dioxolo[4,5-b]pyridine IM13 (1.74 g,
8.61 mmol) in DMF (25 ml) under N2 and tributyl(1-ethoxyvinyl)tin (3.65 ml, 10.8 mmol) was
added. Tetrakistriphenylphosphinepalladium(0) (0.50 g, 0.43 mmol) was added and the solu-
tion was stirred at 65 °C overnight. The mixture was added to water and EtOAc and the
phases were separated. The org phase was washed with brine, dried (MgSO4) filtered and
was rotovaped. The e was dissolved in THF (100 ml), and a mixture of water (15 ml)
and conc. HCI (2.5 ml) was added and the solution was stirred at rt 5 min. The solution was
added to brine and sat NaHC03 solution was added until the solution was slightly alkaline.
The org Phase was extracted with EtOAc and the phases were separated. The org phase
was washed with brine, dried (MgSO4) filtered and was rotovaped. The residue was redis-
solved in THF (10 ml) EtOAc (20 ml) and heptanes (20 ml). The mixture was concentrated
until 25 ml remained and cooled in ice. A solid precipitated and was collected by filtration.
Yield: 0.942 g (66%) of IM21. 1H-NMR (500 MHz, DMSO) 6 8.47 (s,1H), 8.54 (s, 1H), 6.27 (s,
2H), 2.53 (s, 3H).
IM22: 1 -(2, 3-Dihydro-[1
, 4]dioxino[2, 3—b]pyridiny/)-ethanone
[Annotation] sak
Prepared analogously to IM21 from with o-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine (3.00
g, 13.9 mmol) to give the title compound as a white powder (1.84 g, 74%). 1H-NMR (500
MHz, DMSO) 6 8.47 (s, 1H), 8.54 (s, 1H), 6.27 (s, 2H), 2.53 (s, 3H).
IM23: 1-(6-Ethyl—pyridin-3—yl)-ethanone
A dry round bottomed flask was charged with 1-(6-chloropyridinyl)—1-ethanone
(IM15) (3.596 g, 23.11 mmol) and [1 s(dipheny|phosphino)ferrocene]-dichloropalladium(ll)
(1.694 g, 2.315 mmol) in THF (100 mL) under N2. A1 M solution of diethyl zinc in hexane (35
mL, 35 mmol) was added drop wise to this mixture followed by N,N-dimethylaminoethanol
(0.50 mL, 5.0 mmol). The mixture was heated to reflux for 30 minutes. The mixture was
cooled to room temperature and then quenched by the addition of ted aqueous NH4C|
solution (100 mL). The mixture was filtered through a plug of celite. The aqueous layer was
extracted with EtOAc (3x100 mL). The combined organic layers were washed with water,
brine and then dried over Mg2804. Flash Chromatography (120 g silica, 0-40% EtOAc in hep-
tanes) gave the title compound as a yellow oil (0.699 g, 20%) sufficiently pure for the next
step.
Preparation of chiral amines.
Chiral amines were made, if not commercially available, according to well-described proce-
dure for either 1,2-stereoselective reduction of sulfinyl imines or 1,2-stereoseelctive addition
of organometallic reagents to sulfinyl imines. These s have been described by Chel-
lucci, G., Baldino, 8., Chessa, 8., Pinna, G., Soccolini, 8., Tetrahedron Asymmetry 2006, 17,
3163-3169, Evans, J., Ellman, J., J. Org. Chem. 2003, 68, 9948-9957 and Robak, M., Herb-
age, M., Ellman, J., Chem. Rev. 2010, 110, 3600-3740 and nces cited herein.
IM24: (8)(6-Isopropoxy—pyridin-3—yI)-ethy/amine
[>le
mI k\
Ste 1: ion of sulfin l imine:
1-(6-Iso-propoxy-pyridinyl)-ethanone IM16 (3.20 g, 17.8 mmol) was dissolved in THF (55
mL) under N2. R(+)methylpropanesulfinamide (2.21 g, 18.2 mmol) and tita-
[Annotation] sak
nium(|V)ethoxide (7.40 mL, 35.7 mmol) was added. The mixture was refluxed for 24 hours.
The mixture was allowed to reach room temperature. The mixture was diluted with EtOAc
(200 mL) and poured into ice/brine. The ing slurry was filtered through Celite. The or-
ganic layer was washed with brine, dried over M9804 and evaporated to dryness. Flash
chromatography (silica, heptanes/EtOAc 2:1) gave (R)—2-methyl-propanesulfinic acid [1-(6-
isopropoxy-pyridinyl)-ethy|idene]-amide (4.04 g, 80%) as a yellow oil sufficiently pure for
the next step.
Step 2: Reduction of the imine:
A round-bottomed flask was charged with (R)—2-methyl-propanesulfinic acid [1-(6-iso—
propoxy-pyridinyl)—ethylidene]—amide (4.00 g, 14.2 mmol) in THF (50 mL) under N2 and
cooled to -66°C (internal temperature). A 1.00 M solution of L-Selectride in THF (29.0 mL,
29.0 mmol) was added drop wise over 15 minutes. The mixture was d at -70°C for 1
hour. The cold mixture was poured into saturated aqueous NH4CI solution. The mixture was
extracted with EtOAc. The combined organic layers were washed with brine, dried over
M9804 and ated to dryness. Flash chromatography (silica, EtOAc) gave (R)—2-methyl-
propanesulfinic acid [(S)—1-(6-isopropoxy-pyridinyl)—ethyl]—amid (2.91 g, 72%) as a color-
less powder. Diastereomeric excess >95% based on 1H NMR.
Step 3: Removal of chiral auxiliaLy:
(R)—2-Methyl-propanesulfinic acid -(6-isopropoxy-pyridinyl)—ethyl]—amide (2.90 g,
10.2 mmol) was dissolved in methanol (48 mL). A mixture of 12.0 M HCI in water (4.25 mL)
and water (4.25 mL) was added drop wise over 3 minutes. The mixture was stirred at room
temperature overnight. The mixture was ated to dryness. The oily e was sub-
jected to flash chromatography a, EtOAc/EtOH/triethylamine 90:5:5) on a short column to
give (S)—1-(6-isopropoxy-pyridinyl)—ethylamine IM24 (1.71 g, 93%) as a pale-yellow oil suf-
ficiently pure for the next step. The overall yield from 1-(6-isopropoxy-pyridinyl)—ethanone
IM16 was 54%.
IM25: (6-Ethyl—pyridinyl)-ethylamine
Prepared analogously to IM24 from IM23 to give the title compound sufficiently pure for the
next step.
IM26: (S)(6-Methoxymethyl-pyridinyI)-ethy/amine
[Annotation] sak
Prepared analogously to IM24 to give the title compound iently pure for the next step.
IM27: (S)-1 -[6-(2, 2, 2- Trifluoro-ethoxy)-pyridinyl]—ethy/amine
Prepared analogously to IM24 to give the title compound sufficiently pure for the next step.
IM28: (S)[6-(2-Methoxy-ethoxy)-pyridiny/]-ethylamine
Q‘Hz
\ O/\/O\
Prepared analogously to IM24 to give the title compound sufficiently pure for the next step.
IM29: (2-Ethoxy—pyridinyl)-ethy/amine
E‘Hz
Prepared analogously to IM24 to give the title compound sufficiently pure for the next step.
IM30: (S){6-[(S)-(Tetrahydro-furany/)oxy]-pyridiny/}-ethylamine
/N O
\I L)
Prepared analogously to IM24 to give the title compound sufficiently pure for the next step.
IM31 : (S){6-[(R)—(Tetrahydro-furanyl)oxy]-pyridinyl}-ethy/amine
[Annotation] sak
Prepared analogously to IM24 to give the title compound sufficiently pure for the next step.
IM32: (S)[1, 3]Dioxolo[4, 5-b]pyridiny/-ethylamine
ed analogously to IM24 to give the title compound sufficiently pure for the next step.
IM33: (S)(2, dro-[1,4]dioxino[2, 3-b]pyridin- 7-yl)-ethy/amine
Prepared analogously to IM24 to give the title compound sufficiently pure for the next step.
IM34: (S)(2-Ethoxy-pyrimidinyl)-ethy/amine
ed analogously to IM24 to give the title compound sufficiently pure for the next step.
IM35: 2—[5-((S)Amino-ethyl)-pyridin-2—yloxy]-ethanol
E‘Hz
o3 JOH|\
0
Prepared analogously to IM24 to give the title compound sufficiently pure for the next step.
[Annotation] sak
IM36: (R)Amino(6-propoxy—pyridiny/)-ethanol
Br 1 tB) u'L' )(S‘gH
/ N +><S N '
I 2)Separate
Hm THL HOHO
A 1.7 M solution of tert—butyllithium in pentane (15.2 mL, 25.8 mmol) was added drop wise to
a stirring solution of 5-bromopropoxypyridine IM3 (2.54 g, 11.8 mmol) ved in dry THF
(29.4 mL) at -78°C under Ar. The solution was subsequently stirred at this temperature for 30
min. A solution of (R)—2-methyl-propanesulfinic acid [2-(tert-butyl-dimethyl-silanyloxy)—
ethylidene]—amide IM49 (3.26 g, 11.8 mmol) in dry THF (15 mL) was then added drop wise at
-78°C and the solution was stirred at this temperature for 30 min. The cooling bath was re-
moved and the mixture was allowed to reach room temperature overnight. The mixture was
quenched with saturated s NH4CI solution (75 mL) and EtOAc (150 mL). The phases
were separated and the organic layer was washed with brine and then dried over MgSO4.
Flash chromatography (silica, 10-100% EtOAc in heptanes) gave (R)—2-Methyl-propane
sulfinic acid [(R)—2-(tert-butyl-dimethyl-silanyloxy)—1-(6-propoxy-pyridinyl)—ethy|]-amide, the
fastest eluding isomer, as a clear oil (2.33 g, 48%) sufficiently pure for the next step. Di-
astereomeric excess >95% based on 1H NMR.
A 2.00 M solution of en chloride in diethyl ether (28 mL, 56 mmol) was added to a
stirred solution of [(R)—2-(tert-butyl-dimethyl-silanyloxy)—1-(6-propoxy-pyridinyl)-ethy|]-amide
(2.33 g, 5.62 mmol) ved in MeOH (11 mL) at 0°C under Ar. After the addition was com-
pleted the cooling bath was removed and the solution was stirred at room temperature over-
night. The e was then evaporated to dryness and the residue was suspended in methylene
chloride and transferred to a short silica gel column. After eluding with
EtOAc:EtOH:Et3N (90:5:5) (R)—2-Amino(6-propoxy-pyridinyl)-ethano|, IM36, was ob-
tained as an oil (0.813 g, 74%). The l yield from 5-bromopropoxypyridine IM3 was
36%.
1H NMR (600 MHz, CDCI3) 6 8.61 (s, 1H), 8.60 (dd, 1H), 7.71 (d, 1H), 4.22 (t, 2H), 4.06 (m,
1H), 3.72 (m, 1H), 3.60 (m, 1H), 1.78 (m, 2H), 1.24 (m, 1H), 1.02 (m, 4H).
IM37: (R)Amino-2—(6-isopropoxy—pyridin-3—y/)-ethanol
ation] sak
'2‘“2
OH \
Prepared analogously to IM36 to give the title compound sufficiently pure for the next step
(1.07 g, 36% overall yield from IM1).
IM38: (R)Amino(6-ethoxy-pyridinyI)-ethano/
Q‘Hz
OH \
Prepared analogously to IM36 to give the title compound sufficiently pure for the next step
(0.360 g, 35% overall yield from commercially available 5-bromoethoxy-pyridine, Apollo
catalog no OR13065).
IM39: (R)Amino(6-(1, 1, 2, 2, 2-d5)-ethoxy—pyridinyl)-ethanol
OH \
D>H\DD D
ed analogously to IM36 to give the title compound sufficiently pure for the next step
(0.500 g, 22% overall yield from IM5).
IM40: (R)Amino(6-(2, 2, 2-d3)-ethoxy-pyridin-3—y/)-ethanol
Q‘Hz
Prepared analogously to IM36 to give the title compound iently pure for the next step
(0.647 g, 30% overall yield from IM4).
IM41 : (R)Amino(6-(1,1-d2)-ethoxy-pyridiny/)-ethanol
[Annotation] sak
OH \
Prepared ously to IM36 to give the title compound sufficiently pure for the next step
(0.380 g, 18% overall yield from IM6).
IM42: (R)-2—Amino{6-[(S)-(tetrahydro-furanyl)oxy]—pyridinyl}-ethano/
E‘Hz
OH \ [2
Prepared analogously to IM36 to give the title compound sufficiently pure for the next step.
IM43: (R)Amino{6-[(R)-(tetrahydro-furany/)oxy]—pyridinyl}-ethano/
E‘Hz
OH \ IL)
Prepared analogously to IM36 to give the title compound sufficiently pure for the next step.
IM44: (R)Amino-2—(6-cyclobutoxy-pyridiny/)-ethanol
m/N D
Prepared ously to IM36 to give the title compound sufficiently pure for the next step.
IM45: (R)Amino-2—[6-(tetrahydro-pyranyloxy)-pyridiny/]-ethanol
OH \
Prepared analogously to IM36 to give the title compound sufficiently pure for the next step.
Pre aration of carbox lic acids.
[Annotation] sak
IM46: (1 2-Pheny/-cyclopropanecarboxy/ic acid
(3 O
III"V)\OH
Commercially available, racemic trans 2-phenyl-cyclopropanecarboxylic acid (Sigma-Aldrich,
g no P22354) was subjected to chiral SFC separation, method C to give IM46 as an oil
that slowly solidified upon ng. Enantiomeric purity 95% ee (Method F). Specific optical
rotation +300.9° [or]D20 (C = 1% EtOH). (Lit: +389° [or]D20 (C = 0.61, CHCI3) Kozikowski et al., J.
Med. Chem. 2009, 52, 1885-1902), (Lit: +311.7° [or]D20 (C = 1.776, EtOH) Walborsky et al.,
Tetrahedron 1964, 20, 699.)
IM47: (1 S,2S)(3-F/uoro-phenyl)-cyc/opropanecarboxylic acid
F I""V)kOH
Fm Step1 F
//\n/ \/ —>O + 3N / O
Fm LO Q 0
/ OH
0 I""V)kOH
Step 1:
A round-bottomed flask was charged with 3-fluorostyrene (13.0 g, 0.107 mol) in anhydrous
methylene chloride (130 mL). To this mixture was added rhodium acetate dimer (1.30 g, cat
amount). A solution of ethyldiazoacetate (33.28 g, 0.291 mol) in anhydrous methylene chlo-
ride (130 mL) was added to the reaction via a syringe pump over 5 h and stirred at room tem-
perature for 1h in darkness. The reaction mixture was filtered through a plug of , which
was washed with water ed by brine. The c layer was dried over NaZSO4 and
evaporated to dryness. Flash chromatography (silica, EtOAc/petroleum ether 1:9) gave rac-
trans 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid ethyl ester (13.0 g, 59%) as a colorless
liquid sufficiently pure for the next step.
To a solution of rac—trans 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid ethyl ester (13.0 g,
0.062 mol) in MeOH (310 mL) was added a solution of KOH (35.0 g, 0.625 mol) in MeOH
[Annotation] sak
(150 mL) at 0°C. After on of the base the reaction mixture was stirred at room tempera-
ture for 18 h. The reaction e was poured into water and extracted with methylene chlo-
ride (2x50 mL). The aqueous layer was acidified with 10% HCI. The ing mixture was ex-
d with methylene chloride (2x150 mL). The combined organic layers were dried over
N82804 and evaporated to dryness to give rac-trans(3-fluoro-phenyl)-
cyclopropanecarboxylic acid as colorless crystals (9.5 g, 85%). Separation of the isomers by
chiral SFC (Method D) gave the title compound (1S,2S)—2-(3-fluoro-pheny|)-
cyclopropanecarboxylic acid IM47 as colorless crystals (3.27 g, 17% overall yield from 3-
fluorostyrene) iently pure for the next step. Specific optical rotation +263.4° [or]D20 (C =
1% MeOH)
IM48: (1 S, 2S)(4-Fluoro-phenyl)-cyclopropanecarboxy/ic acid
F : 0H
Prepared analogously to IM48 using SFC method E to give the title compound sufficiently
pure for the next step (3.1 g, 13% overall yield from 4-fluorostyrene). Specific optical rotation
+263.2° MD” (0 = 1% MeOH)
Other intermediates.
IM49: (R)Methyl-propanesu/finic acid [2-(terf-butyl-dimethyl-silanyloxy)-ethylidene]—
amide
K/O;Si/
(R)—(+)methylpropanesulfinamide (8.70 g, 71.8 mmol), pyridinium p-toluenesulfonate
(0.902 g, 3.59 mmol) and MgSO4 (43.2 g, 359 mmol) was ded in methylene chloride
(25 mL). A solution of (terf-butyldimethylsilyloxy)acetaldehyde (25.0 g, 144 mmol) dissolved in
methylene chloride (10 mL) was added drop wise at room temperature. The reaction was
stirred at room temperature overnight. The mixture was evaporated to dryness. Flash chro-
matography (silica, EtOAc/heptanes 1:4) gave the title compound as an oil that slowly solidi-
fied upon standing (18.3 g, 92%) sufficiently pure for the next step.
Example 1: Preparation of example nds of the invention:
[Annotation] sak
Compound 1: (1 S, 2S)-2—Pheny/—cyclopropanecarboxy/ic acid [(8)(6-isopropoxy—pyridin-3—
yl)-ethy/]-amide
'E'HZ I"'-V)kNH
VAC“ + | k / N
0 AC» k\
Transphenylcyclopropanecarboxylic acid IM46 (0.590 g, 3.64 mmol) was dissolved in
DMF (15.0 mL). N,N,N’,N’-tetramethyl-O-(7-azabenzotriazolyl)uronium hexafluorophos-
phate (1.38 g, 3.63 mmol) was added. Triethylamine (1.10 mL, 7.89 mmol) was then added
and the mixture was stirred for 15 s at room temperature. This mixture was added drop
wise to a solution of (S)—1-(6-isopropoxy-pyridinyl)-ethylamine IM24 (0.655 g, 3.63 mmol)
dissolved in DMF (15.0 mL) over 2 minutes. The mixture was stirred at room temperature
over night. The mixture was evaporated to s. The residue was transferred to a silica
gel column and eluded with EtOAc/heptanes 1:1 to give Compound 1 as a solid. This solid
was dissolved in EtOAc (50 mL) and to this solution was slowly added es (50 mL). The
mixture was concentrated to approx. 25 mL in vacuo and this solution was cooled in an
ice/water bath. A white precipitate . The solids was collected by filtration and dried in
vacuo to give the title compound as colorless crystals (0.794 g, 67%). LC-MS (m/z) 325.4
(MH+), tR = 1.51 min (method A). 1H NMR (500 MHz, DMSO) 6 8.57 — 8.50 (m, 1H), 8.06 (br
s, 1H), 7.65 — 7.57 (m, 1H), 7.30 — 7.24 (m, 2H), 7.20 — 7.14 (m, 1H), 7.10 (d, J = 7.5 Hz, 2H),
6.69 (d, J = 8.5 Hz, 1H), 5.25 — 5.16 (m, 1H), 4.98 — 4.88 (m, 1H), 2.24 — 2.15 (m, 1H), 1.94 —
1.88 (m, 1H), 1.41 — 1.32 (m, 4H), 1.26 (d, J = 6.2 Hz, 6H), 1.20 (ddd, J = 8.5, 6.1, 4.1 Hz,
1H). Diastereomeric excess >95% based on 1H NMR.
Compound 2: (1 2—Pheny/—cyclopropanecarboxy/ic acid -(5-methy/-pyridin-2—y/)-
ethyIJ-amide
o o 2 VAN“
I""V)LOH + N
\ l
N-(3-Dimethylaminopropyl)—N’-ethylcarbodiimide hydrochloride (0.709 g, 3.70 mmol) and 1-
hydroxybenzotriazole (0.667 g, 4.93 mmol) were added to a stirred mixture of IM46 (0.60 g,
3.70 mmol) and commercially available (S)—1-(5-methyl-pyridinyl)—ethylamine hydrochloride
[Annotation] sak
(Supplier Netchem Inc, Catalog No 528193) (0.426 g, 2.47 mmol) and N,N-
diisopropylethylamine (0.859 ml, 4.93 mmol) in THF (25 ml). The solution was stirred at rt
overnight. Water was added and the mixture was extracted with EtOAc (3x80 ml). The com-
bined organic phases were washed with brine, dried over MgSO4, filtered and the solvent
was evaporated of in vac. The crude product was purified by silica gel tography
(EtOAc in heptanes 1:1). Yield of Compound 2: 110 mg (16%). LC-MS (m/z) 281.1 (MH+), tR
= 0.91 min (method A).
Compound 3: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(S)(6-methoxy—pyridin-B—yD-
ethyIJ-amide
NHz ,,
O NH
kOH / IN —> E
\ 0/ |
\ /
Prepared analogously to Compound 1 using IM46 and commercially available (S)—1-(6-
methoxy-pyridinyl)-ethylamine (Supplier m Inc, Catalog No 517706). Yield = 0.88 g
(66%).1H NMR (500 MHz, DMSO) 6 8.55 (d, 1H), 8.10 (s, 1H), 7.63 (d, 1H), 7.27 (m, 2H),
7.17 (m, 1H), 7.10 (d, 2H), 6.78 (d, 1H), 4.93 (m, 1H), 3.72 (s, 3H), 2.21 (m, 1H), 1.90 (m,
1H), 1.37 (m, 4H), 1.20 (m, 1H). LC-MS (m/z) 297.4 (MH+), tR = 1.36 min (method A).
Compound 4: (1 S,2S)-2—Pheny/—cyclopropanecarboxy/ic acid [(S)(6-methyl—pyridin-3—y/)—
ethyIJ-amide
NHz ,,
:VAOH 0QEO NH
/ N —> E
+ n\
Prepared ously to Compound 1 using IM46 and commercially available (S)—1-(6-
methyl-pyridinyl)-ethylamine (Supplier m Inc, Catalog No 519526). Yield = 0.27 g
(21%).1H NMR (600 MHz, DMSO) 6 8.61 (d, 1H), 8.37 (s, 1H), 7.57 (d, 1H), 7.26 (m, 2H),
7.16 (m, 2H), 7.09 (d, 2H), 4.92 (m, 1H), 2.41 (s, 3H), 2.19 (m, 1H), 1.91 (m, 1H), 1.36 (m,
4H), 1.20 (m, 1H). LC-MS (m/z) 281.2 (MH+), tR = 0.86 min (method A).
[Annotation] sak
Compound 5: (1 S, 2S)Pheny/—cyclopropanecarboxy/ic acid [(S)(6-cyano-pyridiny/)—
ethyIJ-amide
NHz ,,
[::j i '"
o NH
#OH /\©\/ N —> ?
/ |N
\\N \
Prepared ously to Compound 2 using IM46 and cially ble 5-((S)
amino-ethyl)-pyridinecarbonitrile hydrochloride (Supplier Netchem Inc, Catalog No
549493). Yield = 0.104 g (20%). %). 1H NMR (600 MHz, DMSO) 6 8.76 (d, 1H), 8.71 (s, 1H),
8.02 (d, 1H), 7.94 (d, 1H), 7.29 (m, 2H), 7.19 (m, 1H), 7.12 (d, 2H), 5.03 (m, 1H), 2.21 (m,
1H), 1.92 (m, 1H), 1.40 (d, 3H), 1.37 (m, 1H), 1.23 (m, 1H). LC-MS (m/z) 292.0 (MH+), tR =
1.31 min (method A).
Compound 6: (1 S,2S)Pheny/—cyclopropanecarboxy/ic acid [(S)(6-trifluoromethyl-pyridin-
3—y/)-ethy/]—amide
Ell-l2 ,,
O NH
“VAOH N —> ?
' /
\ F r
F \ F
F F
Prepared analogously to Compound 2 using IM46 and commercially available (S)—1-(6-
trifluoromethyl-pyridinyl)—ethylamine hydrochloride. (Supplier Netchem Inc, Catalog No
517662). Yield = 0.33 g (55%). %). 1H NMR (500 MHz, DMSO) 6 8.77 (d, 1H), 8.72 (s, 1H),
7.99 (d, 1H), 7.88 (d, 1H), 7.27 (m, 2H), 7.17 (m, 1H), 7.13 (d, 2H), 5.05 (m, 1H), 2.20 (m,
1H), 1.93 (m, 1H), 1.41 (d, 3H), 1.37 (m, 1H), 1.23 (m, 1H). LC-MS (m/z) 335.2 (MH+), tR =
1.59 min (method A).
Compound 7: (1 S, 2S)Pheny/—cyclopropanecarboxy/ic acid [(S)(6-ethoxy—pyridin-3—yl)-
-amide
gHZ ----:7/JLNH
oowe
[Annotation] sak
Prepared analogously to Compound 2 using IM46 and commercially available (S)—1-(6-
ethoxy-pyridinyl)—ethylamine hydrochloride ier Sial Gmbh, Catalog No 528261-HCI,
Lot no LNA098). Yield = 0.30 g (39%). 1H NMR (500 MHz, DMSO) 6 8.54 (d, 1H), 8.08 (s,
1H), 7.62 (d, 1H), 7.27 (m, 2H), 7.16 (m, 1H), 7.12 (d, 2H), 6.73 (d, 1H), 4.92 (m, 1H), 4.25 (q,
2H), 2.20 (m, 1H), 1.91 (m, 1H), 1.35 (m, 4H), 1.30 (t, 3H), 1.19 (m, 1H). LC-MS (m/z) 311.4
(MH+), tR = 1.45 min (method A).
Compound 8: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(S)(6-ethy/-pyridin-3—yl)-
ethyIJ-amide
NH2 ,,
O NH
1"'V)LOH + IN —> ?
\ IN
Prepared analogously to Compound 1 using IM46 and IM25. Yield = 0.44 g (65%). 1H NMR
(500 MHz, DMSO) 6 8.51 (d, 1H), 8.41 (s, 1H), 7.27-7.14 (m, 4H), 7.10 (d, 2H), 4.96 (m, 1H),
2.72 (q, 2H), 2.20 (m, 1H), 1.92 (m, 1H), 1.38 (m, 4H), 1.21 (m, 4H). LC-MS (m/z) 295.1
(MH+), tR = 0.90 min d A).
nd 9: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(S)(6-methoxymethyl—
pyridinyl)-ethyl]—amide
W12 ,,
O NH
I""V)LOH + IN —> E
\ 0\ IN
\ o\
Prepared analogously to Compound 1 using IM46 and IM26. Yield = 0.18 g (40%). 1H NMR
(500 MHz, DMSO) 6 8.63 (d, 1H), 8.10 (s, 1H), 7.71 (d, 1H), 7.37 (d, 1H), 7.27 (m, 2H), 7.17
(m, 1H), 7.10 (d, 2H), 4.97 (m, 1H), 3.37 (s, 3H), 2.21 (m, 1H), 1.93 (m, 1H), 1.39 (m, 4H),
1.20 (m, 1H). LC-MS (m/z) 311.3 (MH+), tR = 0.98 min (method A).
Compound 10: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid {(S)[6-(2, 2, 2—trifluoro-
ethoxy)-pyridinyl]-ethy/}-amide
[Annotation] sak
NH2 ,,
o '5‘“
V» 2
. N
OH \ F
Io/kF
Prepared analogously to Compound 1 using IM46 and IM27. Yield = 0.695 g (50%). 1H NMR
(500 MHz, DMSO) 6 8.62 (d, 1H), 8.12 (s, 1H), 7.73 (d, 1H), 7.27 (m, 2H), 7.15 (m, 1H), 7.10
(d, 2H), 6.95 (d), 4.97 (m, 3H), 2.20 (m, 1H), 1.91 (m, 1H), 1.37 (m,4H), 1.20 (m, 1H). LC-MS
(m/z) 365.3 (MH+), tR = 1.78 min (method A).
Compound 1 1 : (1 S,28)-2—Phenyl—cyclopropanecarboxylic acid {(8)[6-(2-methoxy—ethoxy)-
pyridin-3—y/]—ethy/}-amide
E'HZ ”””#NH
o0 '
Prepared analogously to Compound 1 using IM46 and IM28. Yield = 0.758 g (30%). 1H NMR
(500 MHz, DMSO) 6 8.57 (d, 1H), 8.08 (s, 1H), 7.65 (d, 1H), 7.26 (m, 2H), 7.17 (m, 1H), 7.10
(d, 2H), 6.78 (d, 1H), 4.92 (m, 2H), 4.32 (m, 2H), 3.62 (m, 2H), 3.27 (s, 3H), 2.20 (m, 1H),
1.89 (m, 1H), 1.37 (m, 4H), 1.20 (m, 1H). LC-MS (m/z) 341.0 (MH+), tR = 1.33 min (method
A).
Compound 12: (1 S, 28)-2—Phenyl—cyclopropanecarboxylic acid [(S)(2-ethoxy—pyridinyl)-
-amide
Isz K E:-
O = O NH K
/ —> ?
+ I O
OH \ N |
Prepared ously to Compound 1 using IM46 and IM29. Yield = 0.11 g (48%). 1H NMR
(500 MHz, DMSO) 6 8.55 (d, 1H), 8.06 (s, 1H), 7.30 (m, 2H), 7.19 (m, 1H), 7.14 (m, 2H), 6.90
(d, 1H), 6.67 (d, 1H), 4.88 (m, 1H), 4.26 (m, 2H), 2.20 (m, 1H), 1.96 (m, 1H), 1.40-1.27 (m,
7H), 1.22 (m, 1H). LC-MS (m/z) 311.4 (MH+), tR = 1.36 min (method A).
[Annotation] sak
Compound 13: (1 S, 2S)Pheny/—cyclopropanecarboxy/ic acid ((S){6—[(S)—(tetrahydro-
furan-3—yl)ony-pyridin-3—yI}-ethy/)-amide
NHz ,,
[ 1 O NH
/ N O
_, E
/ N O
OH Q .Q
0‘ \I D
Prepared ously to Compound 1 using IM46 and IM30. Yield = 0.983 g (62%). 1H-NMR
(500 MHz, DMSO) 6 8.55 (d,1H), 8.09 (s, 1H), 7.64 (d, 1H), 7.27 (m, 2H), 7.16 (m, 1H), 7.11
(d, 2H), 6.78 (d, 1H), 5.48 (m, 1H) 4.96 (m, 1H), 3.92 (m, 1H), 3.85 (m, 1H), 3.74 (m, 2H),
2.21 (m, 2H), 1.95 (m, 2H), 1.37 (m, 4H),1.19 (m, 1H). LC-MS (m/z) 353.3 (MH+), tR = 1.45
min (method A).
nd 14: (1 S, 2S)Pheny/—cyclopropanecarboxy/ic acid ((S){6—[(R)—(tetrahydro-
furan-3—yl)ony-pyridin-3—yI}-ethy/)-amide
Prepared analogously to Compound 1 using IM46 and IM31. Yield = 0.696 g (62%). 1H-NMR
(500 MHz, DMSO) 6 8.56 (d,1H), 8.08 (s, 1H), 7.63 (d, 1H), 7.27 (m, 2H), 7.15 (m, 1H), 7.10
(d, 2H), 6.78 (d, 1H), 5.47 (m, 1H) 4.92 (m, 1H), 3.91 (m, 1H), 3.84 (m, 1H), 3.73 (m, 2H),
2.20 (m, 2H), 1.95 (m, 2H), 1.37 (m, 4H),1.20 (m, 1H). LC-MS (m/z) 353.3 (MH+), tR =1.45
min (method A).
Compound 15: (1 S, 2S)Pheny/—cyclopropanecarboxy/ic acid ((S)[1, 3]dioxo/o[4, 5-
b]pyridinyI-ethyI)-amide
MHZ ,,
O NH
1"'V)LOH /
+ IN a
\ IN
O \
04 O
ed analogously to Compound 1 using IM46 and IM32. Yield = 0.572 g (42%). 1H-NMR
(500 MHZ, DMSO) 6 8.54 (d,1 H), 7.52 (s, 1H), 7.27 (m, 2H), 7.20-7.15 (m, 2H), 7.10 (d, 2H),
[Annotation] sak
6.11 (s, 2H), 4.91 (m, 1H), 2.20 (m, 1H), 1.88 (m, 1H), 1.35 (m, 4H),1.20 (m, 1H). LC-MS
(m/z) 311.1 (MH+), 1R = 0.61 min (method B).
Compound 16: (1 S, 2S)-2—Pheny/—cyclopropanecarboxy/ic acid [(S)(2, 3-dihydro-
[1, 4]dioxino[2, 3-b]pyridin- 7—y/)-ethyl]—amide
Ell-l2 ,,
o NH
«L + flN —>
OH \
o |
o¢ 0
Prepared analogously to Compound 1 using IM46 and IM33. Yield = 0.877 g (39%). 1H-NMR
(500 MHz, DMSO) 6 8.52 (d,1H), 7.68 (s, 1H), 7.27 (m, 2H), 7.22 (s, 1H), 7.18 (m, 1H), 7.10
(d, 2H), 4.92 (m, 1H), 4.37 (d, 2H), 4.22 (d, 2H), 2.20 (m, 1H), 1.90 (m, 1H), 1.35 (m, 4H),1.20
(m, 1H). LC-MS (m/z) 325.5 (MH+), 1R = 1.28 min d A).
Compound 17: (1 S, 28)PhenyI-cyclopropanecarboxy/ic acid [(S)(2-ethoxy-pyrimidin
yl)-ethy/]-amide
NHz ,,
O NH
W ;
+ YINmag fl/
\N o/\
Prepared analogously to Compound 1 using IM46 and IM34. Yield = 0.195 g (32%). 1H-NMR
(600 MHz, DMSO) 6 8.53 , 8.52 (s, 2H), 7.26 (m, 2H), 7.16 (s, 1H), 7.10 (d, 2H), 4.92
(m, 1H), 4.32 (m, 2H), 2.20 (m, 1H), 1.88 (m, 1H), 1.40 (d, 3H), 1.35 (m, 1H), 1.31 (t, 3H),1.20
(m, 1H). LC-MS (m/z) 312.2 (MH+), tR = 0.62 min d B).
Compound 18: (1 S, 2S)-2—Pheny/—cyclopropanecarboxy/ic acid [(S)(6-ch/oro-pyridinyl)-
ethyIJ-amide
NHz ,,
O NH
+ /\CNK
' OH \
Cl |
[Annotation] sak
Prepared analogously to Compound 1 using IM46 and commercially available (S)—1-(6-
Chloro-pyridinyl)-ethylamine a building blocks catalogue nrA06.814.555). Yield =
1.40 g (71%). 1H-NMR (500 MHz, DMSO) 6 8.68 (d,1H), 8.36 (s, 1H), 7.78 (d, 1H), 7.48 (d,
1H), 7.28 (m, 2H), 7.18 (m, 1H), 7.11 (d, 2H), 4.99 (m, 1H), 2.20 (m, 1H), 1.92 (m, 1H), 1.37
(m, 4H),1.20 (m, 1H). LC-MS (m/z) 301.2 and 303.1 (MH+), tR = 0.67 min (method B).
Compound 19: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid {(S)[6-(oxetany/oxy)-
pyridin-3—y/]—ethy/}-amide
© 0 O 0
%w + L —»
\I \
Cl 0
(1 S,2S)Phenyl-cyclopropanecarboxylic acid [(S)—1-(6-chloro-pyridinyl)-ethyl]-amide
(Compound 18) (2.00 g, 6.65 mmol) was dissolved in DMF (50 ml). Oxetanol (4.00 g, 54
mmol) and dicesium carbonate (16.2 g, 49.9 mmol) were added and the mixture was heated
at 100 °C ON. The mixture was poured out into brine and ted with EtOAc. The organic
layer was washed with brine, dried (MgSO4) and was filtered and then evaporated to dry-
ness. The residue was transferred to a silica gel column and eluded with EtOAc/heptanes 1:1
to give Compound 19 as a solid. This solid was dissolved in a mixture of THF (10 ml), EtOAc
(20 mL) and heptanes (10 ml).The mixture was trated to approx. 15 mL in vacuo and
this solution was cooled in an ice/water bath. A white precipitate formed. The solids was col-
lected by tion and dried in vacuo to give the title compound as colorless crystals (0.097 g,
4%). %). 1H-NMR (500 MHz, DMSO) 6 8.55 , 8.04 (s, 1H), 7.70 (d, 1H), 7.25 (m,2H),
7.15 (m, 1H), 7.10 (d, 2H), 6.87 (d, 1H), 5.52 (m, 1H), 4.95 (m, 1H), 4.87 (m, 2H), 4.53 (m,
2H), 2.20 (m, 1H), 1.90 (m, 1H), 1.37 (m, 4H),1.21 (m, 1H). LC-MS (m/z) 339.2 (MH+), tR =
0.63 min (method B). Mp =151-153 C.
nd 20: (1 S,28)-2—Pheny/—cyclopropanecarboxy/ic acid [(S)(6—cyanomethoxy—
pyridin-3—yl)-ethyl]—amide
ation] sak
(>11 "
0 = OH
/ VA'2‘“
+ IN I _’ = OH
Compound 20a
G#0630"r ©Vin
Compound 20b Compound 20
Compound 20a was ed analogously to Compound 1 using IM46 and IM35 for the first
step. Yield of nd 20a = 1.50 g (71%). Pure on TLC (Eluent EtOAc, Rf = 0.5). This
material (1.50 g, 4.36 mmol) was dissolved in a mixture of DMSO (50 ml) and THF (50 ml)
and 1-Hydroxy-1,2-benziodoxol-3(1H)—one 1-Oxide (1.34 g, 4.8 mmol) was added and the
mixture was stirred at rt overnight. The mixture was added to a mixture of brine and EtOAc
and the phases were separated. The organic phases was dried over MgSO4 and was ro-
tovaped. The crude product was purified by silica gel chromatography (Eluent EtOAc). Yield
of Compound 20b = 1.08 g (72%). Pure on TLC (Eluent EtOAc, Rf = 0.7). This material (1.05
g, 3.24 mmol) was dissolved in THF (10 ml), and MeCN (50 ml) and added drop wise to a so-
lution of 1-Hydroxy-1,2-benziodoxol-3(1H)—one e (1.36 g, 4.86 mmol) in ammonia in
water (13 M, 25 ml) and THF (5 ml) and MeCN (5 ml). The mixture was stirred at rt ON.
The organic phases was dried over MgSO4 and was rotovaped. The crude product was puri-
fied by silica gel chromatography (Eluent EtOAc in heptanes 4:1) to give 177 mg impure prod-
uct. This material was THF (10 ml) and EtOAc (10 ml) and heptanes (10 ml) were added. The
mixture was rotovaped until aprox 10 ml solvent was left and then cooled in an ice bath. A
solid precipitated and was collected and dried in vac. Yield of Compound 20 = 0.054 g (5%).
Pure on LCMS and H-NMR. Mp—- 163-165 C. LC-MS (m/z) 322.1 (MH+), tR= 1.03 min
(method A). 1H-NMR (500 MHz, DMSO) 6 8.60 , 8.17 (s, 1H), 7.75 (d, 1H), 7.27 (m,
2H), 7.17 (m, 1H), 7.11 (d, 2H), 6.95 (d, 1H), 5.19 (s, 2H), 4.97 (m, 1H), 2.21 (m, 1H), 1.92
(m, 1H), 1.38 (m, 4H),1.21 (m, 1H).
nd 21: (1 S, 2S)Phenyl—cyclopropanecarboxy/ic acid [(R)hydroxy—1-(6-propoxy—
pyridin-3—y/)-ethy/]—amide
[Annotation] sak
6 z '-
o NH
OH w y 4
OH \I
O OH(U f\
Triethylamine (0.384 mL, 2.75 mmol) was added to a mixture of 2-phenyl
cyclopropanecarboxylic acid IM46 (223 mg, 1.38 mmol) and O-(benzotriazolyl)-N,N,N’,N’-
tetramethyluronium hexafluorophosphate (522 mg, 1.38 mmol) suspended in DMF (2mL) in a
small vial. The vial was vigorously agitated for 30 seconds and then left for 5 minutes. This
mixture was added drop wise to (R)—2-Amino(6-propoxy-pyridinyl)-ethanol IM36 (270
mg, 1.4 mmol) dissolved in DMF (3 mL). After 1 h the mixture was poured into a mixture of
EtOAc (40 mL) and brine (20 mL). The organic layer was dried over MgSO4 and evaporated
to dryness. Flash tography (silica, 10-100% EtOAc in heptanes) gave the title com-
pound as a white solid (0.134 g, 29%). LC-MS (m/z) 341.0 (MH+), tR = 1.52 min (method A).
1H-NMR (600 MHz, DMSO) 6 8.53 (d, J = 8.2 Hz, 1H), 8.04 (br s, 1H), 7.64 — 7.57 (m, 1H),
7.30 — 7.23 (m, 2H), 7.19 — 7.14 (m, 1H), 7.10 (d, J = 7.3 Hz, 2H), 6.74 (d, J = 8.5 Hz,1H),
4.96 — 4.90 (m, 1H), 4.88 — 4.80 (m, 1H), 4.16 (t, J = 6.7 Hz, 2H), 3.61 — 3.49 (m, 2H), 2.23 —
2.15 (m, 1H), 2.04 — 1.95 (m, 1H), 1.74 — 1.64 (m, 2H), 1.40 — 1.32 (m, 1H), 1.23 — 1.13 (m,
1H), 0.94 (t, J = 7.4 Hz, 3H).
Compound 22: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(R)hydroxy—1-(6-
trifluoromethyl—pyridinyl)-ethyl]-amide
NH2 ’1.
6 z '-
o NH
""-V)LOH +
w 2
' /
OH \ F IN
OH \ F
N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (0.39 g, 2.03 mmol) and 1-
hydroxybenzotriazole (0.366 g, 2.71 mmol) were added to a stirred mixture of IM46 (0.22 g,
1.36 mmol) and commercially ble (R)—2-amino(6-trifluoromethyl-pyridinyl)-ethanol
hydrochloride (Supplier Netchem Inc, Catalog No 517882) (0.494 g, 2.03 mmol) and N,N-
diisopropylethylamine (0.472 ml, 2.71 mmol) in THF (20 ml). The solution was d at rt
overnight. Water was added and the mixture was extracted with EtOAc (3x80 ml). The com-
bined organic phases were washed with brine, dried over MgSO4, filtered and the solvent
was evaporated of in vac. The crude product was purified by silica gel chromatography
[Annotation] sak
(EtOAc in heptanes 10:1). Yield of Compound 22 475 mg (78%). 1H-NMR (500 MHz,
DMSO) 6 8.77 (d, 1H), 8.74 (s, 1H), 8.00 (d, 1H), 7.88 (d, 1H), 7.27 (m, 2H), 7.18 (m, 1H),
7.13 (d, 2H), 5.04 (m, 2H), 3.64 (m, 2H), 2.22 (m, 1H), 2.07 (m, 1H), 1.37 (m, 1H), 1.37 (m,
1H), 1.23 (m, 1H). LC-MS (m/z) 351.1 (MH+), tR = 1.51 min (method A).
Compound 23: (1 S,28)-2—Pheny/—cyclopropanecarboxy/ic acid [(R)(5-cyano-pyridin-2—yl)—
2—hydroxy—ethy/J—amide
I l /N
OH OH \
\ |
\ N OH \
Prepared analogously to Compound 22 using IM46 and commercially available 6-((R)—1-
aminohydroxy-ethyl)-nicotinonitrile (Supplier Netchem Inc., Catalog No ). Yield of
Compound 23 230 mg (61%). 1H-NMR (500 MHz, DMSO) 6 8.97 (s, 1H), 8.72 (d, 1H), 8.26
(d, 1H), 7.52 (d, 1H), 7.27 (m, 2H), 7.18 (t, 1H), 7.11 (d, 2H), 5.05-4.95 (m, 2H), 3.70 (m, 2H),
2.20 (m, 1H), 2.17 (m, 1H), 1.36 (m, 1H), 1.20 (m, 1H). LC-MS (m/z) 308.1 (MH+), tR = 1.21
min (method A).
Compound 24: (1 S, 28)-2—Phenyl-cyclopropanecarboxy/ic acid [(R)hydroxy—1-(6-methoxy—
pyridin-3—yl)-ethyl]—amide
MHZ ,,
o NH
'-V)LOH N s
+ | / N
OH \ 0/ I
OH \ /
Prepared analogously to nd 22 using IM46 and commercially available (R)—2-Amino-
ethoxy-pyridinyl)—ethanol (Supplier Netchem Inc., g No 517926). Yield of
Compound 24 = 763 mg (22%). 1H-NMR (500 MHz, DMSO) 6 8.53 (d, 1H), 8.09 (s, 1H),
7.63 (d, 1H), 7.27 (m, 2H), 7.15 (m, 1H), 7.12 (m, 2H), 6.77 (d, 1H), 4.95 (m, 2H), 4.85 (m,
2H), 3.83 (s, 3H), 3.57 (m, 2H), 2.21 (m, 1H), 2.00 (m, 1H), 1.37 (m, 1H), 1.19 (m, 1H). LC-
MS (m/z) 313.1 (MH+), tR = 1.53 min (method A).
Compound 25: (1 S,28)-2—Pheny/—cyclopropanecarboxy/ic acid [(R)hydroxy—1-(6-methyl-
pyridin-3—yl)-ethyl]—amide
[Annotation] sak
0 ©
o EDC.HCI ©V)kIIIIII#NH'-#NH 5
«k _
_’ —> / N
OH N - |
I LIOH 0H \
”Q C compound 25a
N-(3-Dimethylaminopropyl)—N’-ethylcarbodiimide hydrochloride (0.316 g, 1.65 mmol) and 1-
hydroxybenzotriazole (0.223 g, 1.65 mmol) were added to a stirred mixture of IM46 (0.18 g,
1.1 mmol) and commercially available (R)—2-Amino(6-methyl-pyridinyl)-ethanol dihydro-
chloride (Supplier Netchem Inc., Catalog No 549945) (0.128 g, 1.21 mmol) and N,N-
diisopropylethylamine (0.575 ml, 3.30 mmol) in THF (10 ml). The solution was stirred at rt
overnight. Water was added and the mixture was extracted with EtOAc. The organic phase
was rotovaped to produce 140 mg of Compound 25a. LC-MS (m/z) 441.4 (MH+), tR = 1.44
min (method A). Compound 25a was dissolved in THF and LiOH (1 M) was added and the
mixture was stirred 30 min. A solid precipitated and was isolated by filtration and dried in vac.
Yield of Compound 25 = 110 mg (34%). 1H-NMR (500 MHZ, DMSO) 6 8.53 (d, 1H), 8.09 (s,
1H), 7.63 (d, 1H), 7.27 (m, 2H), 7.15 (m, 1H), 7.12 (m, 2H), 6.77 (d, 1H), 4.95 (m, 2H), 4.85
(m, 2H), 3.83 (s, 3H), 3.57 (m, 2H), 2.21 (m, 1H), 2.00 (m, 1H), 1.37 (m, 1H), 1.19 (m, 1H).
LC-MS (m/z) 297.3 (MH+), tR = 0.78 min d A).
Compound 26: (1 S,28)Pheny/—cyclopropanecarboxy/ic acid -hydroxy—1-(6-
isopropoxy—pyridinyI)-ethy/]-amide
Prepared analogously to Compound 21 using IM46 and IM37. Yield of nd 26 = 667
mg (77%). 1H-NMR (600 MHz, DMSO) 6 8.52 (d, 1H), 8.03 (s, 1H), 7.60 (d, 1H), 7.25 (m,
2H), 7.15 (m, 1H), 7.10 (d, 2H), 6.67 (d, 1H), 5.20 (m, 1H), 4.92 (t, 1H), 4.83 (m, 1H), 3.55 (m,
2H), 2.20 (m, 1H), 2.00 (m, 1H), 1.35 (m, 1H), 1.24 (d, 6H), 1.19 (m, 1H). LC-MS (m/z) 341.0
(MH+), tR = 1.45 min (method A).
[Annotation] sak
Compound 27: (1 S,2S)(3—F/uoro-pheny/)-cyc/opropanecarboxylic acid [(R)(6-ethoxy-
pyridin-3—y/)hydroxy-ethyl]—amide
NH2 -
6 g F
o 51H
I""V)kOH +
F OH \' N J
)0 OH \
Prepared analogously to Compound 21 using IM47 and IM38. Yield of Compound 27 = 90
mg (19%). 1H-NMR (600 MHz, DMSO) 6 8.53 (d, 1H), 8.05 (s, 1H), 7.62 (m, 1H), 7.28 (m,
1H), 6.97 (m, 3H), 6.73 (d, 1H), 4.83 (m, 1H), 4.24 (m, 2H), 3.55 (m, 2H), 2.22 (m, 1H), 2.03
(m, 1H), 1.37 (m, 1H), 1.28 (t, 3H), 1.22 (m, 1H). LC-MS (m/z) 345.0 (MH+), tR = 0.63 min
(method B).
Compound 28: (1 S,2S)(4-F/uoro-pheny/)-cyc/opropanecarboxylic acid [(R)(6-ethoxy-
pyridin-3—y/)hydroxy-ethyl]—amide
MHZ , VA
F ; NH
/ E
OH OH \
O I
OH \ J
Prepared analogously to Compound 21 using IM48 and IM38. Yield of Compound 28 = 93
mg white solid. (54%). 1H-NMR (600 MHz, DMSO) 6 8.56 (d, 1H), 8.07 (s, 1H), 7.62 (m, 1H),
7.18 (m, 2H), 7.12 (m, 2H), 6.77 (d, 1H), 4.93 (t, 1H), 4.83 (m, 1H), 4.25 (dd, 2H), 3.52 (m,
2H), 2.27 (m, 1H), 1.97 (m, 1H), 1.30 (m, 4H), 1.15 (m, 1H). LC-MS (m/z) 345.0 (MH+), LCMS
(m/z) 345.0 (MH+), tR = 1.36 min (method A).
Compound 29: (1 2-(3—F/uoro-pheny/)-cyc/opropanecarboxylic acid [(R)hydroxy
(6-propoxy-pyridin-3—yl)-ethyl]-amide
JG a F '-
o NH
""-V)L0H +
—» /
F OH \'
O IN
OH \ J/
ed analogously to Compound 21 using IM47 and IM36. Yield = 150 mg (30%). 1H-
NMR (600 MHz, DMSO) 6 8.53 (d, 1H), 8.03 (s, 1H), 7.62 (d, 1H), 7.29 (m, 1H), 6.95 (m, 3H),
[Annotation] sak
6.74 (d, 1H), 4.93 (m, 1H), 4.84 (m, 1H), 4.16 (t, 2H), 3.55 (m, 2H), 2.23 (m, 1H), 2.03 (m,
1H), 1.68 (m, 2H), 1.37 (m, 1H), 1.25 (m, 1H), 0.93 (t, 3H). LC-MS (m/z) 359.1 (MH+), tR =
1.57 min (method A).
Compound 30: (1 S, 2S)(4-F/uoro-phenyI)-cyclopropanecarboxy/ic acid -hydroxy
(6-propoxy-pyridinyl)-ethyl]-amide
F ,,
(3 ?
o NH
W»... mN+ J/ 3
O /, f
OH \
Prepared analogously to Compound 21 using IM48 and IM36. Yield 176 mg (36%). 1H-NMR
(600 MHz, DMSO) 6 8.52 (d, 1H), 8.05 (s, 1H), 7.63 (d, 1H), 7.14 (m, 2H), 7.09 (m, 2H), 6.74
(d, 1H), 4.92 (t, 1H), 4.85 (m, 1H), 4.15 (t, 2H), 3.55 (m, 2H), 2.22 (m, 1H), 1.97 (m, 1H), 1.70
(m, 2H), 1.34 (m, 1H), 1.18 (m, 1H), 0.92 (t, 3H).
Compound 31: (1 S, 2S)Pheny/—cyclopropanecarboxy/ic acid [(R)(6-(2, 2, 2-d3)-ethoxy-
pyridin-3—y/)hydroxy-ethyl]—amide
[EH—'2 """#NH
#0 a
+ “Q
o /
H OH \ O/\)/D ' D
Prepared ously to Compound 21 using IM46 and IM40. Yield = 785 mg (66%). 1H-
NMR (600 MHz, CDCI3) 6 8.62 (s, 1H), 7.52 (d, 1H), 7.26 (m, 2H), 7.20 (m, 1H), 7.08 (d, 2H),
6.71 (d, 1H), 6.27 (m, 1H), 5.05 (m, 1H), 4.31 (s, 2H), 3.91 (m, 2H), 2.51 (m, 2H), 1.67 (m,
2H), 1.31 (m, 1H). LC-MS (m/z) 330.3 (MH+), tR = 1.32 min (method A).
Compound 32: (1 S, 2S)(3-F/uoro-phenyI)-cyclopropanecarboxy/ic acid [(R)(6-(1,1-d2)-
ethoxy-pyridinyl)hydroxy-ethyl]—amide
[Annotation] sak
Prepared analogously to Compound 21 using IM47 and IM41. Yield = 104 mg (44%). 1H-
NMR (600 MHz, DMSO) 6 8.52 (d, 1H), 8.03 (s, 1H), 7.61 (m, 1H), 7.29 (m, 1H), 6.97 (m,
3H), 6.72 (d, 1H), 4.93 (m, 1H), 4.85 (m, 1H), 3.55 (m, 2H), 2.22 (m, 1H), 2.02 (m, 1H), 1.37
(m, 1H), 1.25 (m, 4H). LC-MS (m/z) 347.2 (MH+), tR = 0.64 min (method A).
Compound 33: (1 S,2S)-2—Pheny/—cyclopropanecarboxy/ic acid [(R)(6-ethoxy—pyridin-3—yl)-
2-hydroxy-ethy/J—amide
NH2 ,,
o NH
'-V)LOH N ?
+ I / N
OH \ /\
O I
ed analogously to Compound 22 using IM46 and IM38. Yield = 90 mg (28%). 1H-NMR
(600 MHz, DMSO) 6 8.53 (d, 1H), 8.06 (s, 1H), 7.52 (m, 1H), 7.26 (m, 2H), 7.16 (m, 1H), 7.10
(d, 2H), 6.73 (d, 1H), 4.95 (t, 1H), 4.87 (m, 1H), 4.25 (m, 2H), 3.55 (m, 2H), 2.20 (m, 1H), 2.02
(m, 1H), 1.36 (m, 1H), 1.28 (t, 3H), 1.20 (m, 1H). LC-MS (m/z) 327.4 (MH+), tR = 0.57 min
d B).
Compound 34: (1 S, 2S)-2—(4-Fluoro-phenyl)-cyc/opropanecarboxy/ic acid [(R)(6-(1, 1,2, 2, 2-
d5)-ethoxy-pyridinyl)-2—hydroxy—ethyl]—amide
F ,,
o 1ng
+ (\CNKD =
D —>
0&0 / N
OH OH \ D D
Prepared analogously to Compound 21 using IM48 and IM39. Yield = 130 mg (41%). 1H-
NMR (600 MHz, DMSO) 6 8.53 (d, 1H), 8.06 (s, 1H), 7.62 (m, 1H), 7.14 (m, 2H), 7.10 (m,
2H), 6.73 (d, 1H), 4.95 (br s, 1H), 4.84 (m, 1H), 3.55 (m, 2H), 2.22 (m, 1H), 1.96 (m, 1H), 1.34
(m, 1H), 1.18 (m, 1H). LC-MS (m/z) 350.2 (MH+), tR = 1.41 min (method A).
Compound 35: (1 S,2S)(4-F/uoro-phenyl)-cyc/opropanecarboxylic acid [(R)(6-(2, 2, 2-d3)-
ethoxy-pyridinyl)-2—hydroxy—ethyl]—amide
[Annotation] sak
Prepared analogously to nd 21 using IM48 and IM40. Yield = 144 mg (41%). 1H-
NMR (600 MHz, DMSO) 6 8.53 (d, 1H), 8.08 (s, 1H), 7.63 (m, 1H), 7.13 (m, 2H), 7.10 (m,
2H), 6.73 (d, 1H), 4.97 (br s, 1H), 4.86 (m, 1H), 4.24 (s, 2H), 3.57 (m, 2H), 2.23 (m, 1H), 1.97
(m, 1H), 1.37 (m, 1H), 1.20 (m, 1H). LC-MS (m/z) 347.9 (MH+), tR = 1.39 min (method A).
Compound 36: (1 S, Phenyl—cyclopropanecarboxy/ic acid [(R)(6-(1, 1 -d2)-ethoxy-
pyridin-3—y/)hydroxy—ethyl]—amide
NHz ,,
(3 z
O NH
/ N E
+ D D
I,"-V)LOH I X —> /
OH D
\ D
0 lN
OH \ OX
Prepared analogously to Compound 21 using IM46 and IM41. Yield = 148 mg (67%). 1H-
NMR (600 MHz, DMSO) 6 8.52 (d, 1H), 8.05 (s, 1H), 7.61 (d, 1H), 7.50 (m, 2H), 7.15 (m, 1H),
7.10 (d, 2H), 6.72 (d, 1H), 4.94 (t, 1H), 4.85 (m, 1H), 3.55 (m, 2H), 2.18 (m, 1H), 1.97 (m, 1H),
1.35 (m, 1H), 1.27 (s, 3H), 1.20 (m, 1H). LC-MS (m/z) 329.2 (MH+), tR = 0.61 min (method B).
Compound 37: (1 S, 2S)-2—(4-F/uoro-phenyI)-cyclopropanecarboxy/ic acid [(R)(6-(1,1-d2)-
ethoxy-pyridinyl)-2—hydroxy—ethyl]—amide
F ,,
o NH
[ I"'-V)LOH+C,):\©D>§/ N E
D D /
O INDD
OH \ ox
Prepared analogously to Compound 21 using IM48 and IM41. Yield = 123 mg (52%). 1H-
NMR (600 MHz, DMSO) 6 8.52 (d, 1H), 8.06 (s, 1H), 7.62 (m, 1H), 7.14 (m, 2H), 7.10 (m,
2H), 6.73 (d, 1H), 4.92 (t, 1H), 4.84 (m, 1H), 3.55 (m, 2H), 2.22 (m, 1H), 1.96 (m, 1H), 1.34
(m, 1H), 1.28 (s, 3H), 1.18 (m, 1H). LC-MS (m/z) 347.2 (MH+), tR = 1.41 min (method B).
[Annotation] sak
Compound 38: (1 S, 2S)Pheny/—cyclopropanecarboxy/ic acid [(R)(6-(1, 1,2, 2, 2-d5)-
ethoxy-pyridinyl)hydroxy-ethyl]—amide
NHZ I «k
E D NH
O D
+ N D E D D
| —>
OH OH \ D
O |
Prepared analogously to Compound 21 using IM46 and IM39. Yield = 98 mg (32%). 1H-NMR
(600 MHz, DMSO) 6 8.52 (d, 1H), 8.05 (s, 1H), 7.61 (d, 1H), 7.26 (t, 2H), 7.16 (t, 1H), 7.10 (d,
2H), 6.72 (d, 1H), 4.93 (t, 1H), 4.83 (m, 1H), 3.55 (m, 2H), 2.18 (m, 1H), 1.99 (m, 1H), 1.35
(m, 1H), 1.20 (m, 1H). LC-MS (m/z) 332.2 (MH+), tR = 0.61 min (method B).
Compound 39: (1 S, 2S)(3-F/uoro-phenyI)-cyclopropanecarboxy/ic acid [(R)(6-(2, 2, 2-d3)-
ethoxy-pyridinyl)hydroxy-ethyl]—amide
'2le
O I F
D D
/ [EIH
+ IN TD - D
’ —> / ND
F OH OH \
0 l
OH \ TD
Prepared analogously to Compound 21 using IM47 and IM40. Yield = 101 mg (29%). 1H-
NMR (600 MHz, DMSO) 6 8.53 (d, 1H), 8.05 (s, 1H), 7.61 (d, 1H), 7.28 (m, 1H), 70-695 (m,
3H), 6.72 (d, 1H), 4.93 (t, 1H), 4.83 (m, 1H), 4.22 (s, 2H), 3.55 (m, 2H), 2.23 (m, 1H), 2.02 (m,
1H), 1.37 (m, 1H), 1.27 (m, 1H). LC-MS (m/z) 348.0 (MH+), tR = 1.43 min (method A).
Compound 40: (1 2-Pheny/—cyclopropanecarboxy/ic acid [(R)(6-cyclobutoxy-pyridin-
3-yl)hydroxy-ethy/]—amide
3‘" z '-
o NH
«k / N E
+ (\Ok D —’ / N
OH OH \
0 ' o/D
OH \
ed analogously to Compound 21 using IM46 and IM44. Yield = 53 mg (30%). 1H-NMR
(600 MHz, DMSO) 6 8.50 (d, 1H), 8.03 (s, 1H), 7.61 (d, 1H), 7.25 (m, 2H) 7.16 (m, 1H), 7.10
(m, 2H), 6.71 (d, 1H), 5.09 (m, 1H), 4.90 (t, 1H), 4.82 (m, 1H), 3.55 (m, 2H), 2.37 (m, 2H),
[Annotation] sak
2.21 (m, 1H), 2.00 (m, 4H), 1.76 (m, 1H), 1.61 (m, 1H), 1.32 (m, 1H), 1.20 (m, -MS
(m/z) 353.1 (MH+), tR = 0.70 min (method B).
Compound 41: (1 S,2S)(3-F/uoro-phenyl)-cyc/opropanecarboxylic acid [(R)(6-
cyc/obutoxy-pyridiny/)hydroxy-ethy/]—amide
NHz ,,
g F
o NH
"'V)kOH m D/+ N ?
I, /
O IN E
OH \
Prepared analogously to Compound 21 using IM47 and IM44. .Yield = 38 mg (20%). 1H-
NMR (600 MHz, DMSO) 6 8.50 (d, 1H), 8.03 (s, 1H), 7.61 (d, 1H), 7.27 (m, 1H), 6.95 (m, 3H),
6.71 (d, 1H), 5.08 (m, 1H), 4.95 (br. s, 1H), 4.82 (m, 1H), 3.55 (m, 2H), 2.37 (m, 2H), 2.22 (m,
1H), 2.02 (m, 4H), 1.75 (m, 1H), 1.61 (m, 1H), 1.37 (m, 1H), 1.27 (m, 1H). LC-MS (m/z) 371.1
(MH+), tR = 0.71 min (method B).
Compound 42: (1 S,2S)(4-F/uoro-phenyl)-cyc/opropanecarboxylic acid [(R)(6-
cyc/obutoxy-pyridiny/)hydroxy-ethy/]—amide
NH2 ,
Fo 3 NH
,, + —>
O OH \
0
ed analogously to Compound 21 using IM48 and lM44.Yie|d = 84 mg (45%). 1H-NMR
(600 MHz, DMSO) 6 8.50 (d, 1H), 8.03 (s, 1H), 7.61 (d, 1H), 7.14 (m, 2H), 7.09 (m, 2H), 6.71
(d, 1H), 5.08 (m, 1H), 4.92 (t, 1H), 4.82 (m, 1H), 3.55 (m, 2H), 2.37 (m, 2H), 2.21 (m, 1H),
2.05-1.95 (m, 4H), 1.75 (m, 1H), 1.61 (m, 1H), 1.32 (m, 1H), 1.17 (m, 1H). LC-MS (m/z) 371.1
(MH+), tR = 0.71 min (method B).
Compound 43: (1 S,28)Pheny/—cyclopropanecarboxylic acid ((R)hydroxy{6-[(R)-
(tetrahydro-furany/)oxy]—pyridiny/}-ethyl)-amide
O EH2 I"-.V)kNH
©”””” -
+ / IN 0
—> / N O
OH \ '
O OH \ (E)
[Annotation] sak
Prepared analogously to Compound 21 using IM46 and IM43. Yield = 1.34 g white solid
(60%).1H NMR (400 MHz, CDCI3): 6 8.08 (s, 1 H), 7.51 (d, J: 8.4 Hz, 1 H), 7.18-7.25 (m, 3
H), 7.04-7.06 (m, 2 H), 6.68-6.71 (m, 1 H), 6.36-6.39 (m, 1 H), 5.50-5.53(m, 1 H), 5.04-
.05(m, 1 H), 3.88-4.01 (m, 6 H), 2.48-2.50 (m, 1 H), 2.21-2.26 (m, 1 H), 2.11-2.13 (m, 1 H),
1.62-1.71 (m, 2 H), 1.27-1.31 (m, 1 H). LC-MS (m/z) 369.2 (MH+), tR = 2.04 min d
WXE-ABO1). [61,30 = 178.6 (C=0.2, CHCI3)
Compound 44: (1 S, 2S)-N-[(1R)hydroxy— 1-[6-[(38)-tetrahydrofuranyljoxy
pyridyljethy/J—2-phenyl-cyclopropanecarboxamide
© 0 VAW
/ O 3
Prepared analogously to Compound 21 using IM46 and IM42. Yield = 2.10 g white solid
(50%). 1H NMR (400 MHz, CDCI3): 68.09 (m, 1 H), 7.52-7.55 (m, 1 H), 7.29 (m, 1 H), 7.25-
7.27 (m, 1 H), 7.20-7.21 (m, 1 H), 7.17-7.19 (d, J: 7.2 Hz, 2 H), .73 (d, J: 8.8 Hz, 1
H), 6.34-6.36 (d, J = 7.2 Hz, 1 H), 5.50-5.53(m, 1 H), 5.04-5.05(d, J = 6.8 Hz, 1 H), 3.94-4.03
(m, 2 H), 3.85-3.91 (m, 4 H), 2.48-2.50 (m, 1 H), 2.21-2.26 (m, 1 H), 2.11-2.13 (m, 1 H), 1.62-
1.71 (m, 2 H), 1.27-1.31 (m, 1 H). LC-MS (m/z) 369.2 (MH+), tR = 2.03 min (method WXEABO1
). [61,30 = 160.9 (c=0.21, CHCI3).
Compound 45: (1 S, 2S)((Z)Methy/ene-penta-2, 4-dienyl)-cyclopropanecarboxy/ic acid
{(R)hydroxy—1-[6-(tetrahydro-pyrany/oxy)-pyridinyl]-ethyl}-amide
'E‘Hz
O '
+ @le
/ N O :
II, —>
'- OH OH \' /IN 0
O OH \
ed analogously to Compound 1 using IM46 and IM45. Yield = 2.5 g white solid (44%).
1H NMR ((400 MHz, CDCI3): 68.09 (s, 1 H), .55 (m, 1 H), .28 (m, 1 H), 7.25-7.26
(m, 1 H), 7.20 (m, 1 H), 7.06-7.08 (t, J: 4.2 Hz, 2 H), 6.70-6.72 (d, J = 8.4 Hz, 1 H), 6.34-6.36
(d, J = 7.2 Hz, 1 H), 5.18-5.21(m, 1 H), 5.04-5.05(d, J: 6.8 Hz, 1 H), 3.62-3.99 (m, 4 H),
[Annotation] sak
3.56-3.62 (m, 2 H), 2.46-2.50 (m, 1 H), 2.01-2.06 (m, 2 H), 1.74-1.80 (m, 2 H), 1.62-1.70 (m, 2
H), 1.27-1.30 (m, 1 H). [011020 = 144.3 (c = 0.204 g/100mL, CHCI3).
Compound 46: (1 S,28)Pheny/—cyclopropanecarboxy/ic acid [(R)(6-ethoxy—pyridinyl)-
2-methoxy—ethy/J—amide
E: 0 0
1,,1'V)k lélH © 1”“?ka
Km :
/ IN
NaH (60 % sion in mineral oil) (2.06 g, 51.5 mmol) was suspended in DMF and the
reaction vessel was cooled in an ice bath. )Phenyl-cyclopropanecarboxylic acid
[(R)(6-ethoxy-pyridinyl)hydroxy-ethyl]—amide (Compound 33) (15 g, 46 mmol) was
dissolved in DMF (50 ml) and added drop wise to the sodium hydride suspension at 5-8 C
over 20 minutes. The on was stirred 30 minutes. Methyl iodide (3.30 ml, 53.0 mmol) dis-
solved in DMF (25 ml) was added drop wise at 5-12 C over 10 minutes and the e was
stirred at 7-8 C for 30 minutes. The mixture was added to a brine solution and extracted with
EtOAc. The organic layer was washed with more brine, dried (MgSO4) filtered and the sol-
vent was evaporated off. The crude product was purified by silica gel chromatography t
EtOAc in heptanes 4:1 ). The fractions that contained the t was collected and the sol-
vent was removed in vac. The residue was redissolved in THF (50 ml) EtOAc (100 ml) and
heptanes (25 ml). The mixture was concentrated until 40 ml remained and cooled in ice. A
white solid precipitated and was collected by filtration. Yield: 6.75 g (43%) of Compound 46.
LC-MS (m/z) 341.2 (MH+), tR = 0.64 min (method B).
1H-NMR (500 MHz, DMSO) 6 8.62 (d,1H), 8.08 (br s, 1H), 7.63 (d, 1H), 7.27 (m, 2H), 7.17
(m, 1H), 7.10 (d, 2H), 6.74 (d, 1H), 5.05 (m, 1H), 4.26 (m, 2H), 3.55 — 3.46 (m, 2H), 3.26 (s,
3H), 2.20 (m, 1H), 1.99 (m, 1H), 1.38 (m, 1H), 1.29 (t, 3H), 1.20 (m, 1H).
Compound 47: (1 S, 2S)-N-[(1R)-2—methoxy—1-[6-[(3R)-tetrahydrofuranyl]oxy—3-
/Jethy/]phenyl-cyc/opropanecarboxamide
E: 0 © 0
[1"1,V)LI¥H ,,,,,'V)LNH
(\O O / N O
I L) I L)
OH \ /O \
O 0
Prepared analogously to Compound 46 using Compound 43 (0.90 g).
[Annotation] sak
Yield = 490 mg (53%) as a solid. 1H NMR (400 MHz, CDCI3): 68.12 (d, J = 2.4 Hz, 1 H), 7.54-
7.57 (m, 1 H), 7.25-7.28 (m, 2 H), 7.18-7.21 (m, 1 H), 7.05-7.07 (m, 2 H), 6.68-6.70 (d, J: 8.8
Hz, 1 H), 6.37-6.39 (d, J: 8.0 Hz, 1 H), 5.51-5.54 (m, 1 H), 5.10-5.12(m, 1 H), .04 (m,
4 H), 3.66-3.69 (m, 1 H), 3.60-3.63 (m, 1 H), 3.38 (s, 3 H), 2.45-2.46 (m, 1 H), 2.21-2.26 (m, 1
H), 1.60-1.68 (m, 2 H), 1.25-1.28 (m, 1 H). LC-MS: 1R = 0.53 min (method B), m/z = 383.2 [M
+ H]+. [011,30 = 188.2 (C=0.176, CHCI3).
Compound 48: (1 S, 2S)-N-[(1R)methoxy[6-[(3S)-tetrahydrofuran-B—y/Joxy
pyridy/Jethy/]—2-phenyl-cyc/opropanecarboxamide
© 0 0
_> © ,VjLNH #NH
I I
OH \ [2 o \
/ [2
o 0
Prepared analogously to Compound 46 using Compound 44 (841 mg).
Yield = 645 mg (44%) as a solid. 1H NMR (400 MHz, CDCI3): 68.10-8.11 (d, J: 2.4 Hz, 1 H),
7.54-7.57 (m, 1 H), 7.25-7.28 (m, 2 H), .21 (m, 1 H), .07 (m, 2 H), 6.68-6.70 (d, J
= 8.8 Hz, 1 H), 6.37-6.39 (d, J: 8.0 Hz, 1 H), 5.51-5.54 (m, 1 H), 5.10-5.12(m, 1 H), 3.87-
4.04 (m, 4 H), 3.66-3.69 (m, 1 H), 3.60-3.63 (m, 1 H), 3.38 (s, 3 H), 2.45-2.46 (m, 1 H), 2.21-
2.26 (m, 1 H), 1.60-1.68 (m, 2 H), 1.25-1.28 (m, 1 H). LC-MS: tR = 0.62 min (method B), m/z
= 383.2 [M + H]+. [011,30 = 162.5 (C=0.225, CHCI3).
Compound 49: (1 S,2S)Pheny/—cyclopropanecarboxy/ic acid {(R)methoxy—1-[6-
(tetrahydro-pyranyloxy)-pyridiny/]-ethyI}-amide
Prepared analogously to Compound 46 using Compound 45. Yield = 343 mg (20%) as a
solid. 1H NMR (400 MHz, CDCI3): 68.10-8.11 (d, J: 2.4 Hz, 1 H), 7.54-7.57 (m, 1 H), 7.25-
7.29 (m, 2 H), 7.18-7.21 (m, 1 H), 7.05-7.07 (m, 2 H), 6.66-6.68 (t, J: 4.2 Hz, 1 H), 6.38-6.40
(d, J = 7.2 Hz, 1 H), .21 (m, 1 H), .12(m, 1 H), 3.94-3.99 (m, 2 H), 3.57-3.69 (m, 4
H), 3.37 (s, 3 H), 2.42-2.49 (m, 1 H), .08 (m, 2 H), 1.61-1.79 (m, 4 H), 1.25-1.28 (m, 1
H) d1D2° = 1593 (c = 0.198 g/100mL, . LC-MS (m/z) 383.15 (MH+), 1R = 0.54 min
(method B).
[Annotation] sak
Compound 50: (1 S, Phenyl—cyclopropanecarboxy/ic acid -[6-(oxetany/oxy)-
pyridin-3—y/]—ethy/}-amide
© 0 O O
VA?“ 1",,
1,",
+ [L NH
—> VA
HCI \
/ /
CI [Tl
(1 S,2S)Phenyl-cyclopropanecarboxylic acid [(S)—1-(6-chloro-pyridinyl)-ethyl]-amide
(Compound 18) (2.00 g, 6.65 mmol) was dissolved in DMF (40 ml). N,N-
dimethylhydroxylaminehydrochloride (5.00 g, 51.2 mmol) and dicesium carbonate (25 g, 76.7
mmol) were added and the mixture was heated at 95 C 3 days. The mixture was poured out
into brine and extracted with EtOAc. The organic layer was washed with brine, dried )
and was filtered and then evaporated to dryness. The residue was transferred to a silica gel
column and eluded with EtOAc to give Compound 50 as a solid. This solid was dissolved in
a mixture of THF (10 ml), EtOAc (10 ml) and heptanes (10 ml).The mixture was concentrated
to approx. 10 ml volume and this solution was cooled in an ice/water bath. A white precipitate
formed. The solids was collected by filtration and dried in vacuo to give the title compound as
a white solid (0.044 g, 2%). 1H-NMR (500 MHz, DMSO) 6 8.43 (d,1H), 8.02 (s, 1H), 7.45 (d,
1H), 7.25 (m,2H), 7.17 (m, 1H), 7.10 (d, 2H), 6.61 (d, 1H), 4.83 (m, 1H), 3.98 (m, 6H), 2.19
(m, 1H), 1.90 (m, 1H), 1.35 (m, 4H),1.21 (m, 1H). LC-MS (m/z) 310.2 (MH+), tR = 0.46 min
(method B). Mp 81 C.
Compound 51: (1 S, 2S)-2—Phenyl—cyclopropanecarboxylic acid -(6-ethanesulfonyl
-pyridinyl)-ethyl]—amide
[>le
E: '
0 =
/ VAIIZ I
""V)kOH + IN :
\ / 0
S x IN
8\ \ fif’f’
ed analogously to Compound 1 using IM46 and (S)—1-(6-Methanesulfonyl-pyridin
yl)-ethylamine (prepared from 1-(6-Methanesulfonyl-pyridineyl)—ethanone analogously to
IM24, which was prepared from commercially available 5-Bromomethanesulfonyl-pyridine
CAS 986260). Yield from IM46 = 1.54 g (68%). 1H-NMR (500 MHz, DMSO) 6 8.80
(d,1H), 8.72 (s, 1H), 8.02 (m, 2H), 7.27 (m, 2H), 7.20 (s, 1H), 7.12 (d, 2H), 5.08 (m, 1H), 3.27
[Annotation] sak
(s, 3H), 2.20 (m, 1H), 1.95 (m, 1H), 1.42 (d, 3H), 1.37 (m, 1H),1.22 (m, 1H). LC-MS (m/z)
345.1 (MH+), tR = 1.21 min (method A).
Compound 52: (1 S, 2S)-2—Phenyl—cyclopropanecarboxy/ic acid [(R)(5-ethoxy—pyridin-
2-yl)hydroxy—ethy/]—amide
MHZ ,. VA
3 NH
0 N .
1"'V)LOH I /
OH \
O I
Prepared analogously to Compound 21 using IM46 and Amino(5-ethoxy-pyridin
hanol (prepared from commercially available 2-Bromoethoxy-pyridine CAS 42834
analogously to lM36). Compound 52 was further purified by SFC (Column: Chiralpack
OJ250x30 mm, Mobile phase: Supercrital C02/MeOH+NH4OH = 55/45 at 50 , column
temperature: 38°C, Nozzle Pressure: 100 Bar, Nozzle Temp = 60°C, Evaporator temp = 20 C,
r temp =25°C, Detector: 220 nm). Yield = 163 mg. 1H NMR (CDCI3 400MHz, TMS): 6
8.15 (d, J = 2.8 Hz, 1 H), 7.08-7.31 (m, 6 H), 7.06 (d, J = 7.2 Hz, 2 H), 5.11-5.15 (m, 1 H),
4.00-4.08 (m, 3 H), 3.87-3.90 (m, 1 H), 2.47-2.52 (m, 1 H), 1.63-1.76 (m, 3 H), 1.43 (t, J = 7.2
Hz, 3 H), 1.27-1.31 (m, 1 H); [01]20,D = 182.0 (c = 0.234 g/100mL, EtOH)
In vitro assays
The nicotinic acetylcholine or 07 is a calcium-permeable ion channel, whose ac-
tivity can be measured by over expression in mammalian cells or oocytes. These two individ-
ual assays are described in Example 2 and 3, respectively.
Example 2: 017 NNR flux assay
The nicotinic acetylcholine receptor 07 is a m-permeable ion channel, whose ac-
tivity can be measured by over expression in mammalian cells or oocytes. In this version of
the assay, the human 07 receptor is stably expressed in the rat GH4C1 cell line. The assay
was used to identify positive allosteric modulators (PAMs) of the 017 receptor. Activation of the
channel was measured by loading cells with the calcium-sensitive fluorescent dye Calcium-4
(Assay kit from Molecular Devices), and then measuring real-time s in fluorescence
upon treatment with test compounds.
[Annotation] sak
The cell line ChanClone GH4C1-nAChRalpha7 from Genionics was seeded from frozen stock
in 384-well plates in culture media 2-3 days before experiment to form an approximately 80%
confluent layer on the day of experiment.
Cell plating and dye loading
The cell culture were split into “22.5cm x 22.5cm”-plates with imately 100x103
cells/cm2. After four days incubation in a humidified incubator at 37°C and 5% C02, it had
grown to an 80-90% confluent layer, and the cells were harvested.
Culture media:
500 mL 12 (Gibco 31331)
50 mL FBS (Gibco 10091-155, lot 453269FD)
mL Sodium Pyruvate (Gibco 11360)
mL Pen/Strep (Gibco 15140)
0.1 mg/mL Gibco11811-064)
Two or three days before the experiment the cells were seeded in 384 well plates from
Greiner bio-one (781946, CELLCOAT, Poly-D-Lysine, black, uClear).
The media was poured off and the plate washed with PBS and left to drain. 5 mL Trypsin was
added, cells were washed and ted (at room temperature) for about 10 seconds. Tryp-
sin was poured of quickly and the cells were incubated for 2 s at 37°C (if the cells were
not already detached). Cells were resuspended in 10 mL culture media and transfered to 50
mL tubes.
The cell suspension was counted (NucleoCounter, total cell count) from the first plates
to estimate the total cell number of the whole batch.
The cells were seeded in 384 well plates with 30 l (30000 cells/well) while stirring the
cell suspension or otherwise preventing the cells from precipitating.
The plates were incubated at room temperature for 30-45 minutes.
The plates were placed in incubator for two days (37°C and 5% C02).
Loading the Cells
The loading buffer was 5% v/v Calcium-4 Kit and 2.5 mM Probenecid in assay buffer.
190 mL assay buffer
mL lution
2 mL 250 mM Probenecid
This volume was enough for 3 x 8 cell plates.
Culture media were removed from the cell plates and 20 uL loading buffer was added
in each well. The cell plates were placed in trays and incubated 90 minutes in the incubator
[Annotation] sak
. Thereafter the plates were incubated 30 minutes at toom temperature, still protected
from light.
Now the cell plates were ready to run in the Functional Drug Screening System
(FDSS).
The assay buffer was HBSS with 20 mM HEPES, pH 7.4 and 3 mM CaClz.
FDSS Ca assay
200 nL 10 mM compound solution in DMSO was diluted in 50 uL assay buffer. The fi-
nal test concentrations in the cell plates were 205-2.5-1.25-0.625-0.312-0.156
0.039 uM. Assay buffer and 3 uM PNU-120596 were used for l.
The agonist acetylcholine was added to a final concentration of 20 uM (~EC100).
In the FDSS7000 the Ex480-Em540 was ed with 1 second intervals. The ne was
made of 5 frames before addition of test compounds, and 95 frames more were made before
addition of acetylcholine. The measurement d 30 frames after the 2nd addition.
Raw data for each well were collected as “the maximum fluorescence count” in the interval
100-131 seconds and as “the average fluorescence count” in the interval 96-100 seconds.
The positive allosteric modulation in the 2nd addition was the enhancement of agonist re-
sponse with test compound compared to agonist alone.
Results were calculated as % modulation of test compound ed to the reference
PNU-120596 set to 100%. From these data EC50 curves were generated giving EC50, hill and
maximum ation.
The compounds of the invention were shown to be PAMs of the o7 receptor. The com-
pounds of the present invention characterized in the flux assay generally possess EC50 val-
ues below 20.000 nM or less such as below 10.000 nM. Many compounds, in fact have EC50
values below 5.000 nM. Table 1 shows EC50 values for exemplified compounds of the inven-
tion.
Table 1
E0000 E0000 E0000
[Annotation] sak
Example 3: a7NNR oocyte assay
Expression of (17 nACh ors in Xenopus oocytes.
Oocytes were surgically removed from mature female Xenepus laevis anaesthetized
in 0.4% MS—222 for 10 — 15 min. The oocytes were then digested at room temperature for 2-3
hours with 0.5 mg/mL collagenase (type IA Sigma-Aldrich) in 0R2 buffer (82.5 mM NaCl, 2.0
mM KCI, 1.0 mM MgClz and 5.0 mM HEPES, pH 7.6). Oocytes avoid of the follicle layer were
selected and incubated for 24 hours in Modified Barth's Saline buffer (88 mM NaCl, 1 mM
KCI, 15 mM HEPES, 2.4 mM NaHCOs, 0.41 mM CaClz, 0.82 mM MgSO4, 0.3 mM Ca(NOs)2)
supplemented with 2 mM sodium pyruvate, 0.1 U/l llin and 0.1 ug/l streptomycin. Stage
IV oocytes were identified and ed with 4.2 - 48 hi of nuclease free water ning 0.1 —
1.2 ng of cRNA coding for human (17 nACh receptors or 3.0 — 32 ng of cRNA coding for rat o7
nACh receptors and incubated at 18°C for 1 — 10 days when they were used for electro-
physiological recordings.
Electrophysiological ings of (17 nACh receptors sed in oocytes.
Oocytes were used for electrophysiological recordings 1 — 10 days after injection.
Oocytes were placed in a 1 mL bath and perfused with Ringer buffer (115 mM NaCl, 2.5 mM
KCI, 10 mM HEPES, 1.8 mM CaClz, 0.1 mM MgClz, pH 7.5). Cells were impaled with agar
plugged 0.2 — 1 M0 odes containing 3 M KCI and voltage clamped at -90 mV by a Ge-
neClamp 500B amplifier. The experiments were performed at room temperature. Oocytes
were continuously perfused with Ringer buffer and the drugs were applied in the perfusate.
ACh (30 uM) applied for 30 sec were used as the standard agonist for activation of the (17
[Annotation] sak
nACh receptors. In the standard screening set-up the new test compound (10 uM or 30 uM)
were applied for 1 min of pre-application allowing for evaluation of agonistic ty followed
by 30 sec of co-application with ACh (30 uM) allowing for evaluation of PAM ty. The re-
sponse of co-application was compared to the agonistic response obtained with ACh alone.
The drug induced effects on both the peak response and the total charge (AUC) response
were calculated thus giving the effect of drug induced PAM ty as fold modulation of the
control response.
For more elaborate studies doses-response curves can be performed for evaluation of
max-fold modulation and E050 values for both peak and AUC responses.
WE
Claims (14)
1. A nd according to formula [I] R3 R5 R6 R2 N A R1 A R11 9 wherein R1, R2, R3, R4 and R5 are H; R6 is methoxymethyl; A7 is C-R7, A8 is N and A9 is C-R9; R7, R9, R10 and R11 are selected ndently of each other from H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy and OR12; wherein R12 represents a monocyclic saturated ring moiety having 4-6 ring atoms wherein one of said ring atoms is O and the rest is C; and ceutically acceptable salts thereof.
2. The nd according to claim 1, wherein R7, R10 and R11 all represent H.
3. The compound according to claim 1 or 2, wherein R9 is C1-4alkoxy.
4. The compound according to claim 1 or 2, wherein R9 is OR12, wherein R12 represents a monocyclic saturated ring moiety having 4-6 ring atoms wherein one of said ring atoms is O and the rest is C.
5. The compound according to any one of claims 1-4 having a diastereomeric excess of at least 80%, such as at least 85%, such as at least 90%, such as at least 95%.
6. The compound according to claim 1selected from 46: (1S,2S)Phenyl-cyclopropanecarboxylic acid [(R)(6-ethoxy-pyridinyl)methoxy- ethyl]-amide; 47: (1S,2S)-N-[(1R)methoxy[6-[(3R)-tetrahydrofuranyl]oxypyridyl]ethyl]phenyl- cyclopropanecarboxamide; 48: (1S,2S)-N-[(1R)methoxy[6-[(3S)-tetrahydrofuranyl]oxypyridyl]ethyl]phenyl- cyclopropanecarboxamide; 49: (1S,2S)Phenyl-cyclopropanecarboxylic acid {(R)methoxy[6-(tetrahydro-pyran yloxy)-pyridinyl]-ethyl}-amide; and pharmaceutically acceptable salts of any of these compounds.
7. The compound according to claim 1, which is 46: (1S,2S)Phenyl-cyclopropanecarboxylic acid -(6-ethoxy-pyridinyl)methoxy- -amide; and pharmaceutically acceptable salts thereof.
8. The compound according to claim 15, which is 47: )-N-[(1R)methoxy[6-[(3R)-tetrahydrofuranyl]oxypyridyl]ethyl]phenyl- cyclopropanecarboxamide; and pharmaceutically acceptable salts thereof.
9. The compound according to claim 1, which is 48: (1S,2S)-N-[(1R)methoxy[6-[(3S)-tetrahydrofuranyl]oxypyridyl]ethyl]phenyl- cyclopropanecarboxamide; and pharmaceutically acceptable salts thereof.
10. The compound according to claim 1, which is 49: (1S,2S)Phenyl-cyclopropanecarboxylic acid {(R)methoxy[6-(tetrahydro-pyran yloxy)-pyridinyl]-ethyl}-amide; and pharmaceutically acceptable salts f.
11. A compound according to any one of claims 1-10, for use as a medicament.
12. A compound according to any one of claims 1-10, for use in the ent of a disease or disorder selected from psychosis; schizophrenia; cognitive disorders; cognitive ment associated with schizophrenia; attention deficit hyperactivity disorder (ADHD); au- tism spectrum disorders, Alzheimer’s disease (AD); mild cognitive impairment (MCI); age associated memory impairment (AAMI); senile ia; AIDS dementia; Pick's disease; dementia associated with Lewy bodies; dementia associated with Down's syndrome; Huntington's disease; Parkinson’s disease (PD); obsessive-compulsive disorder (OCD); tic brain injury; epilepsy; post-traumatic stress; Wernicke-Korsakoff syndrome (WKS); post- traumatic amnesia; cognitive deficits associated with depression; diabetes, weight control, inflammatory disorders, reduced angiogenesis; amyotrophic lateral sclerosis and pain.
13. A pharmaceutical composition comprising a compound according to any of claims 1- 10, and one or more pharmaceutically acceptable carrier or ent.
14. A kit comprising a nd according to any of claims 1-10, er with a second compound selected from the list consisting of acetylcholinesterase inhibitors; glutamate receptor antagonists; dopamine transport inhibitors; noradrenalin transport inhibitors; D2 antagonists ; D2 partial ts; PDE10 antagonists; 5-HT2A antagonists; 5-HT6 antagonists; KCNQ antagonists; lithium; sodium l blockers and GABA signaling enhancers. H. Lundbeck A/S By the Attorneys for the Applicant SPRUSON & FERGUSON Per:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201100520 | 2011-07-08 | ||
DKPA201100520 | 2011-07-08 | ||
NZ617367A NZ617367B2 (en) | 2011-07-08 | 2012-07-06 | Positive allosteric modulators of nicotinic acetylcholine receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ710003A NZ710003A (en) | 2017-01-27 |
NZ710003B2 true NZ710003B2 (en) | 2017-04-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114127053B (en) | Substituted pyrazine compound, preparation method and application thereof | |
US9889122B2 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
KR100245955B1 (en) | Tricyclic antipsychotic compounds | |
AU2017203014B2 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
WO2014049133A1 (en) | New positive allosteric modulators of nicotinic acetylcholine receptor | |
NZ710003B2 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
WO2014090731A1 (en) | New positive allosteric modulators of nicotinic acetylcholine receptor | |
NZ617367B2 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
TW201315731A (en) | New positive allosteric modulators of nicotinic acetylcholine receptor | |
OA19541A (en) | Positive Allosteric Modulators of Nicotinic Acetylcholine Receptor. | |
OA17441A (en) | Positive allosteric modulators of nicotinic acetylcholine receptor. |